{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:57:45Z","timestamp":1791640665500,"version":"4.3.4"},"reference-count":331,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100011011","name":"Junta de Andaluc\u00eda","doi-asserted-by":"crossref","award":["P20_00501"],"award-info":[{"award-number":["P20_00501"]}],"id":[{"id":"10.13039\/501100011011","id-type":"DOI","asserted-by":"crossref"}]},{"name":"European Social Funds","award":["EQC2018-004803-P"],"award-info":[{"award-number":["EQC2018-004803-P"]}]},{"name":"Margarita Salas fellowship, Ministerio de Universidades, Gobierno de Espa\u00f1a"},{"name":"Proyectos de Generaci\u00f3n de Conocimiento, Ministerio de Ciencia e Innovaci\u00f3n, Gobierno de Espa\u00f1a","award":["PID2021-127617NA-I00"],"award-info":[{"award-number":["PID2021-127617NA-I00"]}]},{"name":"Ram\u00f3n y Cajal grant, Ministerio de Ciencia e Innovaci\u00f3n, Gobierno de Espa\u00f1a","award":["PID2021-127617NA-I00"],"award-info":[{"award-number":["PID2021-127617NA-I00"]}]},{"DOI":"10.13039\/100009473","name":"Universidad de M\u00e1laga","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009473","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s40263-023-01017-4","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T05:03:31Z","timestamp":1687323811000},"page":"599-637","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Turning the Spotlight to Cholinergic Pharmacotherapy of the Human Language System"],"prefix":"10.1007","volume":"37","author":[{"given":"Guadalupe","family":"D\u00e1vila","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Torres-Prioris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"L\u00f3pez-Barroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6393-3487","authenticated-orcid":false,"given":"Marcelo L.","family":"Berthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,21]]},"reference":[{"key":"1017_CR1","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1016\/S0028-3932(02)00067-2","volume":"40","author":"SJ Gotts","year":"2002","unstructured":"Gotts SJ, Della Rocchetta AI, Cipolotti L. Mechanisms underlying perseveration in aphasia: evidence from a single case study. Neuropsychologia. 2002;40:1930\u201347. https:\/\/doi.org\/10.1016\/S0028-3932(02)00067-2.","journal-title":"Neuropsychologia"},{"key":"1017_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-017-15981-7","author":"JY Jung","year":"2017","unstructured":"Jung JY, Williams SR, Sanaei Nezhad F, Lambon Ralph MA. GABA concentrations in the anterior temporal lobe predict human semantic processing. Sci Rep. 2017. https:\/\/doi.org\/10.1038\/S41598-017-15981-7.","journal-title":"Sci Rep"},{"key":"1017_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/J.NEUBIOREV.2020.09.023","volume":"119","author":"W Li","year":"2020","unstructured":"Li W, Kutas M, Gray JA, et al. The role of glutamate in language and language disorders: evidence from ERP and pharmacologic studies. Neurosci Biobehav Rev. 2020;119:217\u201341. https:\/\/doi.org\/10.1016\/J.NEUBIOREV.2020.09.023.","journal-title":"Neurosci Biobehav Rev"},{"key":"1017_CR4","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1080\/02687038.2020.1769987","volume":"35","author":"ML Berthier","year":"2021","unstructured":"Berthier ML. Ten key reasons for continuing research on pharmacotherapy for post-stroke aphasia. Aphasiology. 2021;35:824\u201358.","journal-title":"Aphasiology"},{"key":"1017_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/BS10100161","author":"N Sajid","year":"2021","unstructured":"Sajid N, Friston KJ, Ekert JO, et al. Neuromodulatory control and language recovery in bilingual aphasia: an active inference approach. Behav Sci. 2021. https:\/\/doi.org\/10.3390\/BS10100161.","journal-title":"Behav Sci"},{"key":"1017_CR6","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1055\/S-2004-837244","volume":"25","author":"P McNamara","year":"2004","unstructured":"McNamara P, Albert ML. Neuropharmacology of verbal perseveration. Semin Speech Lang. 2004;25:309\u201321. https:\/\/doi.org\/10.1055\/S-2004-837244.","journal-title":"Semin Speech Lang"},{"key":"1017_CR7","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1080\/02687038.2021.1957082","volume":"36","author":"ML Berthier","year":"2022","unstructured":"Berthier ML, Santana-Moreno D, Beltr\u00e1n-Corbellini \u00c1, et al. Controlling the past, owning the present, and future: cholinergic modulation decreases semantic perseverations in a person with post-stroke aphasia. Aphasiology. 2022;36:1293\u2013311. https:\/\/doi.org\/10.1080\/02687038.2021.1957082.","journal-title":"Aphasiology"},{"key":"1017_CR8","doi-asserted-by":"publisher","first-page":"e1619","DOI":"10.1212\/WNL.0000000000200930","volume":"99","author":"N Cedres","year":"2022","unstructured":"Cedres N, Ferreira D, Nemy M, et al. Association of cerebrovascular and Alzheimer disease biomarkers with cholinergic white matter degeneration in cognitively unimpaired individuals. Neurology. 2022;99:e1619\u201329. https:\/\/doi.org\/10.1212\/WNL.0000000000200930.","journal-title":"Neurology"},{"key":"1017_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009444.PUB3","author":"Y Li","year":"2015","unstructured":"Li Y, Hai S, Zhou Y, Dong BR. Cholinesterase inhibitors for rarer dementias associated with neurological conditions. Cochrane Database Syst Rev. 2015. https:\/\/doi.org\/10.1002\/14651858.CD009444.PUB3.","journal-title":"Cochrane Database Syst Rev"},{"key":"1017_CR10","doi-asserted-by":"publisher","first-page":"S120","DOI":"10.1038\/sj.bjp.0706474","volume":"147","author":"DA Brown","year":"2006","unstructured":"Brown DA. Acetylcholine. Br J Pharmacol. 2006;147:S120\u20136. https:\/\/doi.org\/10.1038\/sj.bjp.0706474.","journal-title":"Br J Pharmacol"},{"key":"1017_CR11","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/978-3-030-49586-2_19","volume-title":"Neurovascular neuropsychology","author":"ML Berthier","year":"2020","unstructured":"Berthier ML, D\u00e1vila G, L\u00f3pez-Barroso D, et al. Pharmacological treatment of post-stroke cognitive deficits. In: Lazar RM, Pavol M, Browndyke J, editors., et al., Neurovascular neuropsychology. 2nd ed. New York: Springer Science + Business Media. Behavioral Sciences; 2020. p. 465\u2013500.","edition":"2"},{"key":"1017_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/J.BANDL.2022.105205","author":"ML Berthier","year":"2023","unstructured":"Berthier ML, Edelkraut L, L\u00f3pez-Gonz\u00e1lez FJ, et al. Donepezil alone and combined with intensive language-action therapy on depression and apathy in chronic post-stroke aphasia: a feasibility study. Brain Lang. 2023. https:\/\/doi.org\/10.1016\/J.BANDL.2022.105205.","journal-title":"Brain Lang"},{"key":"1017_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.5853\/JOS.2020.05015","volume":"23","author":"J Fridriksson","year":"2021","unstructured":"Fridriksson J, Hillis AE. Current approaches to the treatment of post-stroke aphasia. J Stroke. 2021;23:183\u2013201. https:\/\/doi.org\/10.5853\/JOS.2020.05015.","journal-title":"J Stroke"},{"key":"1017_CR14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.14283\/JPAD.2018.43","volume":"6","author":"H Hampel","year":"2019","unstructured":"Hampel H, Mesulam MM, Cuello AC, et al. Revisiting the cholinergic hypothesis in Alzheimer\u2019s disease: emerging evidence from translational and clinical research. J Prev Alzheimers Dis. 2019;6:2\u201315. https:\/\/doi.org\/10.14283\/JPAD.2018.43.","journal-title":"J Prev Alzheimers Dis."},{"key":"1017_CR15","doi-asserted-by":"publisher","first-page":"E1580","DOI":"10.1212\/WNL.0000000000007247","volume":"92","author":"MM Mesulam","year":"2019","unstructured":"Mesulam MM, Lalehzari N, Rahmani F, et al. Cortical cholinergic denervation in primary progressive aphasia with Alzheimer pathology. Neurology. 2019;92:E1580\u20138. https:\/\/doi.org\/10.1212\/WNL.0000000000007247.","journal-title":"Neurology"},{"key":"1017_CR16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/J.ARCHGER.2009.11.004","volume":"52","author":"JL Molinuevo","year":"2011","unstructured":"Molinuevo JL, Berthier ML, Rami L. Donepezil provides greater benefits in mild compared to moderate Alzheimer\u2019s disease: implications for early diagnosis and treatment. Arch Gerontol Geriatr. 2011;52:18\u201322. https:\/\/doi.org\/10.1016\/J.ARCHGER.2009.11.004.","journal-title":"Arch Gerontol Geriatr"},{"key":"1017_CR17","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1093\/BRAIN\/AWY132","volume":"141","author":"H Hampel","year":"2018","unstructured":"Hampel H, Mesulam MM, Cuello AC, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease. Brain. 2018;141:1917\u201333. https:\/\/doi.org\/10.1093\/BRAIN\/AWY132.","journal-title":"Brain"},{"key":"1017_CR18","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/J.CLINTHERA.2010.06.019","volume":"32","author":"MR Farlow","year":"2010","unstructured":"Farlow MR, Salloway S, Tariot PN, et al. Effectiveness and tolerability of high-dose (23 mg\/d) versus standard-dose (10 mg\/d) donepezil in moderate to severe Alzheimer\u2019s disease: a 24-week, randomized, double-blind study. Clin Ther. 2010;32:1234\u201351. https:\/\/doi.org\/10.1016\/J.CLINTHERA.2010.06.019.","journal-title":"Clin Ther"},{"key":"1017_CR19","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/J.JALZ.2009.04.1236","volume":"5","author":"S Ferris","year":"2009","unstructured":"Ferris S, Ihl R, Robert P, et al. Severe Impairment Battery Language scale: a language-assessment tool for Alzheimer\u2019s disease patients. Alzheimers Dement. 2009;5:375\u20139. https:\/\/doi.org\/10.1016\/J.JALZ.2009.04.1236.","journal-title":"Alzheimers Dement"},{"key":"1017_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/ALZRT84","author":"SH Ferris","year":"2011","unstructured":"Ferris SH, Schmitt FA, Saxton J, et al. Analyzing the impact of 23 mg\/day donepezil on language dysfunction in moderate to severe Alzheimer\u2019s disease. Alzheimers Res Ther. 2011. https:\/\/doi.org\/10.1186\/ALZRT84.","journal-title":"Alzheimers Res Ther."},{"key":"1017_CR21","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1159\/000340056","volume":"33","author":"J Cummings","year":"2012","unstructured":"Cummings J, Froelich L, Black SE, et al. Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm2) in Alzheimer\u2019s disease. Dement Geriatr Cogn Disord. 2012;33:341\u201353. https:\/\/doi.org\/10.1159\/000340056.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1017_CR22","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1002\/GPS.4080","volume":"29","author":"G Alva","year":"2014","unstructured":"Alva G, Isaacson R, Sadowsky C, et al. Efficacy of higher-dose 13.3 mg\/24 h (15 cm2) rivastigmine patch on the Alzheimer\u2019s Disease Assessment Scale-cognitive subscale: domain and individual item analysis. Int J Geriatr Psychiatry. 2014;29:920\u20137. https:\/\/doi.org\/10.1002\/GPS.4080.","journal-title":"Int J Geriatr Psychiatry"},{"key":"1017_CR23","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/GPS.2738","volume":"27","author":"SF Carter","year":"2012","unstructured":"Carter SF, Caine D, Burns A, et al. Staging of the cognitive decline in Alzheimer\u2019s disease: insights from a detailed neuropsychological investigation of mild cognitive impairment and mild Alzheimer\u2019s disease. Int J Geriatr Psychiatry. 2012;27:423\u201332. https:\/\/doi.org\/10.1002\/GPS.2738.","journal-title":"Int J Geriatr Psychiatry"},{"key":"1017_CR24","doi-asserted-by":"publisher","first-page":"901","DOI":"10.3233\/JAD-142910","volume":"47","author":"S Cloutier","year":"2015","unstructured":"Cloutier S, Chertkow H, Kergoat MJ, et al. Patterns of cognitive decline prior to dementia in persons with mild cognitive impairment. J Alzheimers Dis. 2015;47:901\u201313. https:\/\/doi.org\/10.3233\/JAD-142910.","journal-title":"J Alzheimers Dis"},{"key":"1017_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0089864","author":"KJ Ballard","year":"2014","unstructured":"Ballard KJ, Savage S, Leyton CE, et al. Logopenic and nonfluent variants of primary progressive aphasia are differentiated by acoustic measures of speech production. PLoS ONE. 2014. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0089864.","journal-title":"PLoS ONE"},{"key":"1017_CR26","doi-asserted-by":"publisher","first-page":"E500","DOI":"10.1212\/WNL.0000000000200750","volume":"99","author":"AM Garc\u00eda","year":"2022","unstructured":"Garc\u00eda AM, Welch AE, Mandelli ML, et al. Automated detection of speech timing alterations in autopsy-confirmed nonfluent\/agrammatic variant primary progressive aphasia. Neurology. 2022;99:E500\u201311. https:\/\/doi.org\/10.1212\/WNL.0000000000200750.","journal-title":"Neurology"},{"key":"1017_CR27","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/J.CORTEX.2021.10.010","volume":"146","author":"JA Matias-Guiu","year":"2022","unstructured":"Matias-Guiu JA, Su\u00e1rez-Coalla P, Yus M, et al. Identification of the main components of spontaneous speech in primary progressive aphasia and their neural underpinnings using multimodal MRI and FDG-PET imaging. Cortex. 2022;146:141\u201360. https:\/\/doi.org\/10.1016\/J.CORTEX.2021.10.010.","journal-title":"Cortex"},{"key":"1017_CR28","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1055\/S-0039-1681041","volume":"39","author":"N Villain","year":"2019","unstructured":"Villain N, Dubois B. Alzheimer\u2019s disease including focal presentations. Semin Neurol. 2019;39:213\u201326. https:\/\/doi.org\/10.1055\/S-0039-1681041.","journal-title":"Semin Neurol"},{"key":"1017_CR29","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/J.PSCYCHRESNS.2013.10.003","volume":"221","author":"SJ Teipel","year":"2014","unstructured":"Teipel SJ, Flatz W, Ackl N, et al. Brain atrophy in primary progressive aphasia involves the cholinergic basal forebrain and Ayala\u2019s nucleus. Psychiatry Res. 2014;221:187\u201394. https:\/\/doi.org\/10.1016\/J.PSCYCHRESNS.2013.10.003.","journal-title":"Psychiatry Res"},{"key":"1017_CR30","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/J.NICL.2016.11.027","volume":"13","author":"J Schaeverbeke","year":"2016","unstructured":"Schaeverbeke J, Evenepoel C, Bruffaerts R, et al. Cholinergic depletion and basal forebrain volume in primary progressive aphasia. Neuroimage Clin. 2016;13:271\u20139. https:\/\/doi.org\/10.1016\/J.NICL.2016.11.027.","journal-title":"Neuroimage Clin."},{"key":"1017_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0022-510X(02)00256-3","volume":"203\u2013204","author":"R Kalaria","year":"2002","unstructured":"Kalaria R. Similarities between Alzheimer\u2019s disease and vascular dementia. J Neurol Sci. 2002;203\u2013204:29\u201334. https:\/\/doi.org\/10.1016\/S0022-510X(02)00256-3.","journal-title":"J Neurol Sci"},{"key":"1017_CR32","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1161\/STROKEAHA.117.018889","volume":"49","author":"M Barbay","year":"2018","unstructured":"Barbay M, Taillia H, N\u00e9d\u00e9lec-Ciceri C, et al. Prevalence of poststroke neurocognitive disorders using National Institute of Neurological Disorders and Stroke-Canadian Stroke Network, VASCOG Criteria (Vascular Behavioral and Cognitive Disorders), and Optimized Criteria of Cognitive Deficit. Stroke. 2018;49:1141\u20137. https:\/\/doi.org\/10.1161\/STROKEAHA.117.018889.","journal-title":"Stroke"},{"key":"1017_CR33","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S1474-4422(21)00377-X","volume":"21","author":"NI Bohnen","year":"2022","unstructured":"Bohnen NI, Yarnall AJ, Weil RS, et al. Cholinergic system changes in Parkinson\u2019s disease: emerging therapeutic approaches. Lancet Neurol. 2022;21:381\u201392. https:\/\/doi.org\/10.1016\/S1474-4422(21)00377-X.","journal-title":"Lancet Neurol"},{"key":"1017_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/FNEUR.2023.1128566","author":"H Watanabe","year":"2023","unstructured":"Watanabe H, Hikida S, Ikeda M, Mori E. Aphasic mild cognitive impairment in prodromal dementia with Lewy bodies. Front Neurol. 2023. https:\/\/doi.org\/10.3389\/FNEUR.2023.1128566.","journal-title":"Front Neurol"},{"key":"1017_CR35","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/13554794.2020.1795204","volume":"26","author":"S Boes","year":"2020","unstructured":"Boes S, Botha H, Machulda M, et al. Dementia with Lewy bodies presenting as logopenic variant primary progressive Aphasia. Neurocase. 2020;26:259\u201363. https:\/\/doi.org\/10.1080\/13554794.2020.1795204.","journal-title":"Neurocase"},{"key":"1017_CR36","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1002\/ana.25979","volume":"89","author":"M Buciuc","year":"2021","unstructured":"Buciuc M, Whitwell JL, Kasanuki K, et al. Lewy body disease is a contributor to logopenic progressive aphasia phenotype. Ann Neurol. 2021;89:520\u201333. https:\/\/doi.org\/10.1002\/ana.25979.","journal-title":"Ann Neurol"},{"key":"1017_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/J.ENSCI.2020.100241","author":"K Kakinuma","year":"2020","unstructured":"Kakinuma K, Baba T, Ezura M, et al. Logopenic aphasia due to Lewy body disease dramatically improved with donepezil. eNeurologicalSci. 2020. https:\/\/doi.org\/10.1016\/J.ENSCI.2020.100241.","journal-title":"eNeurologicalSci."},{"key":"1017_CR38","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/J.NEURON.2012.08.036","volume":"76","author":"MR Picciotto","year":"2012","unstructured":"Picciotto MR, Higley MJ, Mineur YS. Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior. Neuron. 2012;76:116\u201329. https:\/\/doi.org\/10.1016\/J.NEURON.2012.08.036.","journal-title":"Neuron"},{"key":"1017_CR39","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/S11910-009-0066-X","volume":"9","author":"SL Small","year":"2009","unstructured":"Small SL, Llano DA. Biological approaches to aphasia treatment. Curr Neurol Neurosci Rep. 2009;9:443\u201350. https:\/\/doi.org\/10.1007\/S11910-009-0066-X.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"1017_CR40","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/NRNEUROL.2010.201","volume":"7","author":"ML Berthier","year":"2011","unstructured":"Berthier ML, Pulverm\u00fcller F. Neuroscience insights improve neurorehabilitation of poststroke aphasia. Nat Rev Neurol. 2011;7:86\u201397. https:\/\/doi.org\/10.1038\/NRNEUROL.2010.201.","journal-title":"Nat Rev Neurol"},{"key":"1017_CR41","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/02687038.2013.818099","volume":"28","author":"D Cahana-Amitay","year":"2014","unstructured":"Cahana-Amitay D, Albert ML, Oveis A. Psycholinguistics of aphasia pharmacotherapy: asking the right questions. Aphasiology. 2014;28:133\u201354. https:\/\/doi.org\/10.1080\/02687038.2013.818099.","journal-title":"Aphasiology"},{"key":"1017_CR42","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/J.NEUROIMAGE.2017.11.056","volume":"190","author":"G Hartwigsen","year":"2019","unstructured":"Hartwigsen G, Saur D. Neuroimaging of stroke recovery from aphasia: insights into plasticity of the human language network. Neuroimage. 2019;190:14\u201331. https:\/\/doi.org\/10.1016\/J.NEUROIMAGE.2017.11.056.","journal-title":"Neuroimage"},{"key":"1017_CR43","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/B978-0-12-823384-9.00013-X","volume":"185","author":"MD Stockbridge","year":"2022","unstructured":"Stockbridge MD. Better language through chemistry: augmenting speech-language therapy with pharmacotherapy in the treatment of aphasia. Handb Clin Neurol. 2022;185:261\u201372. https:\/\/doi.org\/10.1016\/B978-0-12-823384-9.00013-X.","journal-title":"Handb Clin Neurol"},{"key":"1017_CR44","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1126\/SCIENCE.279.5357.1714","volume":"279","author":"MP Kilgard","year":"1998","unstructured":"Kilgard MP, Merzenich MM. Cortical map reorganization enabled by nucleus basalis activity. Science. 1998;279:1714\u20138. https:\/\/doi.org\/10.1126\/SCIENCE.279.5357.1714.","journal-title":"Science"},{"key":"1017_CR45","doi-asserted-by":"publisher","first-page":"5992","DOI":"10.1523\/JNEUROSCI.0230-09.2009","volume":"29","author":"D Ramanathan","year":"2009","unstructured":"Ramanathan D, Tuszynski MH, Conner JM. The basal forebrain cholinergic system is required specifically for behaviorally mediated cortical map plasticity. J Neurosci. 2009;29:5992\u20136000. https:\/\/doi.org\/10.1523\/JNEUROSCI.0230-09.2009.","journal-title":"J Neurosci"},{"key":"1017_CR46","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/J.PNEUROBIO.2011.06.002","volume":"94","author":"P Bentley","year":"2011","unstructured":"Bentley P, Driver J, Dolan RJ. Cholinergic modulation of cognition: insights from human pharmacological functional neuroimaging. Prog Neurobiol. 2011;94:360\u201388. https:\/\/doi.org\/10.1016\/J.PNEUROBIO.2011.06.002.","journal-title":"Prog Neurobiol"},{"key":"1017_CR47","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S0893-6080(02)00058-8","volume":"15","author":"AJ Yu","year":"2002","unstructured":"Yu AJ, Dayan P. Acetylcholine in cortical inference. Neural Netw. 2002;15:719\u201330. https:\/\/doi.org\/10.1016\/S0893-6080(02)00058-8.","journal-title":"Neural Netw"},{"key":"1017_CR48","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/NPP.2010.104","volume":"36","author":"ME Hasselmo","year":"2011","unstructured":"Hasselmo ME, Sarter M. Modes and models of forebrain cholinergic neuromodulation of cognition. Neuropsychopharmacology. 2011;36:52\u201373. https:\/\/doi.org\/10.1038\/NPP.2010.104.","journal-title":"Neuropsychopharmacology"},{"key":"1017_CR49","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.neuroimage.2014.12.036","volume":"108","author":"AS Berry","year":"2015","unstructured":"Berry AS, Blakely RD, Sarter M, Lustig C. Cholinergic capacity mediates prefrontal engagement during challenges to attention: evidence from imaging genetics. Neuroimage. 2015;108:386\u201395. https:\/\/doi.org\/10.1016\/j.neuroimage.2014.12.036.","journal-title":"Neuroimage"},{"key":"1017_CR50","doi-asserted-by":"publisher","first-page":"9446","DOI":"10.1523\/JNEUROSCI.1676-18.2018","volume":"38","author":"L Z\u00e1borszky","year":"2018","unstructured":"Z\u00e1borszky L, Gombkoto P, Varsanyi P, et al. Specific basal forebrain-cortical cholinergic circuits coordinate cognitive operations. J Neurosci. 2018;38:9446\u201358. https:\/\/doi.org\/10.1523\/JNEUROSCI.1676-18.2018.","journal-title":"J Neurosci"},{"key":"1017_CR51","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1002\/HBM.24417","volume":"40","author":"HCJ Fritz","year":"2019","unstructured":"Fritz HCJ, Ray N, Dyrba M, et al. The corticotopic organization of the human basal forebrain as revealed by regionally selective functional connectivity profiles. Hum Brain Mapp. 2019;40:868\u201378. https:\/\/doi.org\/10.1002\/HBM.24417.","journal-title":"Hum Brain Mapp"},{"key":"1017_CR52","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1523\/JNEUROSCI.1305-19.2019","volume":"40","author":"M Sarter","year":"2020","unstructured":"Sarter M, Lustig C. Forebrain cholinergic signaling: wired and phasic, not tonic, and causing behavior. J Neurosci. 2020;40:712\u20139. https:\/\/doi.org\/10.1523\/JNEUROSCI.1305-19.2019.","journal-title":"J Neurosci"},{"key":"1017_CR53","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1002\/CNE.23415","volume":"521","author":"MM Mesulam","year":"2013","unstructured":"Mesulam MM. Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer\u2019s disease. J Comp Neurol. 2013;521:4124\u201344. https:\/\/doi.org\/10.1002\/CNE.23415.","journal-title":"J Comp Neurol"},{"key":"1017_CR54","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1038\/S42003-022-04281-0","volume":"5","author":"PN Alves","year":"2022","unstructured":"Alves PN, Forkel SJ, Corbetta M, Thiebaut de Schotten M. The subcortical and neurochemical organization of the ventral and dorsal attention networks. Commun Biol. 2022;5:1343. https:\/\/doi.org\/10.1038\/S42003-022-04281-0.","journal-title":"Commun Biol"},{"key":"1017_CR55","doi-asserted-by":"publisher","first-page":"16616","DOI":"10.1073\/PNAS.1315235110\/-\/DCSUPPLEMENTAL\/PNAS.201315235SI.PDF","volume":"110","author":"E Fedorenko","year":"2013","unstructured":"Fedorenko E, Duncan J, Kanwisher N. Broad domain generality in focal regions of frontal and parietal cortex. Proc Natl Acad Sci USA. 2013;110:16616\u201321. https:\/\/doi.org\/10.1073\/PNAS.1315235110\/-\/DCSUPPLEMENTAL\/PNAS.201315235SI.PDF.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1017_CR56","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1093\/BRAIN\/AWAC070","volume":"145","author":"MJ O\u2019Sullivan","year":"2022","unstructured":"O\u2019sullivan MJ, Oestreich LKL, Wright P, Clarkson AN. Cholinergic and hippocampal systems facilitate cross-domain cognitive recovery after stroke. Brain. 2022;145:1698\u2013710. https:\/\/doi.org\/10.1093\/BRAIN\/AWAC070.","journal-title":"Brain"},{"key":"1017_CR57","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/ANA.21866","volume":"68","author":"DJ Sharp","year":"2010","unstructured":"Sharp DJ, Turkheimer FE, Bose SK, et al. Increased frontoparietal integration after stroke and cognitive recovery. Ann Neurol. 2010;68:753\u20136. https:\/\/doi.org\/10.1002\/ANA.21866.","journal-title":"Ann Neurol"},{"issue":"Pt 12","key":"1017_CR58","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1093\/BRAIN\/121.12.2249","volume":"121","author":"NR Selden","year":"1998","unstructured":"Selden NR, Gitelman DR, Salamon-Murayama N, et al. Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain. 1998;121(Pt 12):2249\u201357. https:\/\/doi.org\/10.1093\/BRAIN\/121.12.2249.","journal-title":"Brain"},{"key":"1017_CR59","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/NRN2113","volume":"8","author":"G Hickok","year":"2007","unstructured":"Hickok G, Poeppel D. The cortical organization of speech processing. Nat Rev Neurosci. 2007;8:393\u2013402. https:\/\/doi.org\/10.1038\/NRN2113.","journal-title":"Nat Rev Neurosci"},{"key":"1017_CR60","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/NRN.2016.23","volume":"17","author":"MA Skeide","year":"2016","unstructured":"Skeide MA, Friederici AD. The ontogeny of the cortical language network. Nat Rev Neurosci. 2016;17:323\u201332. https:\/\/doi.org\/10.1038\/NRN.2016.23.","journal-title":"Nat Rev Neurosci"},{"key":"1017_CR61","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/J.CUB.2012.09.011","volume":"22","author":"E Fedorenko","year":"2012","unstructured":"Fedorenko E, Duncan J, Kanwisher N. Language-selective and domain-general regions lie side by side within Broca\u2019s area. Curr Biol. 2012;22:2059\u201362. https:\/\/doi.org\/10.1016\/J.CUB.2012.09.011.","journal-title":"Curr Biol"},{"key":"1017_CR62","doi-asserted-by":"publisher","first-page":"9999","DOI":"10.1523\/JNEUROSCI.3642-16.2017","volume":"37","author":"IA Blank","year":"2017","unstructured":"Blank IA, Fedorenko E. Domain-general brain regions do not track linguistic input as closely as language-selective regions. J Neurosci. 2017;37:9999\u201310011. https:\/\/doi.org\/10.1523\/JNEUROSCI.3642-16.2017.","journal-title":"J Neurosci"},{"key":"1017_CR63","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/J.BRAINRES.2010.05.088","volume":"1346","author":"JH Hong","year":"2010","unstructured":"Hong JH, Jang SH. Neural pathway from nucleus basalis of Meynert passing through the cingulum in the human brain. Brain Res. 2010;1346:190\u20134. https:\/\/doi.org\/10.1016\/J.BRAINRES.2010.05.088.","journal-title":"Brain Res"},{"key":"1017_CR64","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/B978-0-12-823384-9.00002-5","volume":"185","author":"LD Bunker","year":"2022","unstructured":"Bunker LD, Hillis AE. Vascular syndromes: revisiting classification of poststroke aphasia. Handb Clin Neurol. 2022;185:37\u201355. https:\/\/doi.org\/10.1016\/B978-0-12-823384-9.00002-5.","journal-title":"Handb Clin Neurol"},{"key":"1017_CR65","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/ANA.410420114","volume":"42","author":"S Minoshima","year":"1997","unstructured":"Minoshima S, Giordani B, Berent S, et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer\u2019s disease. Ann Neurol. 1997;42:85\u201394. https:\/\/doi.org\/10.1002\/ANA.410420114.","journal-title":"Ann Neurol"},{"key":"1017_CR66","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/J.JALZ.2008.04.006","volume":"4","author":"Y Zhou","year":"2008","unstructured":"Zhou Y, Dougherty JH, Hubner KF, et al. Abnormal connectivity in the posterior cingulate and hippocampus in early Alzheimer\u2019s disease and mild cognitive impairment. Alzheimers Dement. 2008;4:265\u201370. https:\/\/doi.org\/10.1016\/J.JALZ.2008.04.006.","journal-title":"Alzheimers Dement"},{"key":"1017_CR67","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.3233\/JAD-200567","volume":"77","author":"D Bergeron","year":"2020","unstructured":"Bergeron D, Beauregard JM, Jean-Guimond, et al. Posterior cingulate cortex hypometabolism in non-amnestic variants of Alzheimer\u2019s disease. J Alzheimers Dis. 2020;77:1569\u201377. https:\/\/doi.org\/10.3233\/JAD-200567.","journal-title":"J Alzheimers Dis"},{"key":"1017_CR68","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0306-4522(98)00304-2","volume":"89","author":"G \u0160imi\u0107","year":"1999","unstructured":"\u0160imi\u0107 G, Mrzljak L, Fu\u010di\u0107 A, et al. Nucleus subputaminalis (Ayala): the still disregarded magnocellular component of the basal forebrain may be human specific and connected with the cortical speech area. Neuroscience. 1999;89:73\u201389. https:\/\/doi.org\/10.1016\/S0306-4522(98)00304-2.","journal-title":"Neuroscience"},{"key":"1017_CR69","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1212\/WNL.0B013E3182886A76","volume":"80","author":"EE Benarroch","year":"2013","unstructured":"Benarroch EE. Pedunculopontine nucleus: functional organization and clinical implications. Neurology. 2013;80:1148\u201355. https:\/\/doi.org\/10.1212\/WNL.0B013E3182886A76.","journal-title":"Neurology"},{"key":"1017_CR70","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/CNE.902830414","volume":"283","author":"M-M Mesulam","year":"1989","unstructured":"Mesulam M-M, Geula C, Bothwell MA, Hersh LB. Human reticular formation: cholinergic neurons of the pedunculopontine and laterodorsal tegmental nuclei and some cytochemical comparisons to forebrain cholinergic neurons. J Comp Neurol. 1989;283:611\u201333. https:\/\/doi.org\/10.1002\/CNE.902830414.","journal-title":"J Comp Neurol"},{"key":"1017_CR71","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/J.NEURON.2017.02.027","volume":"94","author":"J Mena-Segovia","year":"2017","unstructured":"Mena-Segovia J, Bolam JP. Rethinking the pedunculopontine nucleus: from cellular organization to function. Neuron. 2017;94:7\u201318. https:\/\/doi.org\/10.1016\/J.NEURON.2017.02.027.","journal-title":"Neuron"},{"key":"1017_CR72","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/J.NEURON.2016.09.006","volume":"91","author":"EC Ballinger","year":"2016","unstructured":"Ballinger EC, Ananth M, Talmage DA, Role LW. Basal forebrain cholinergic circuits and signaling in cognition and cognitive decline. Neuron. 2016;91:1199\u2013218. https:\/\/doi.org\/10.1016\/J.NEURON.2016.09.006.","journal-title":"Neuron"},{"key":"1017_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/S41467-020-15514-3","author":"D Dautan","year":"2020","unstructured":"Dautan D, Huerta-Ocampo I, Gut NK, et al. Cholinergic midbrain afferents modulate striatal circuits and shape encoding of action strategies. Nat Commun. 2020. https:\/\/doi.org\/10.1038\/S41467-020-15514-3.","journal-title":"Nat Commun"},{"key":"1017_CR74","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/J.BRAINRES.2004.08.050","volume":"1026","author":"RR Garc\u00eda","year":"2004","unstructured":"Garc\u00eda RR, Montiel JF, Villal\u00f3n AU, et al. AChE-rich magnopyramidal neurons have a left-right size asymmetry in Broca\u2019s area. Brain Res. 2004;1026:313\u20136. https:\/\/doi.org\/10.1016\/J.BRAINRES.2004.08.050.","journal-title":"Brain Res"},{"key":"1017_CR75","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1006\/BRLN.1995.1035","volume":"49","author":"TL Hayes","year":"1995","unstructured":"Hayes TL, Lewis DA. Anatomical specialization of the anterior motor speech area: hemispheric differences in magnopyramidal neurons. Brain Lang. 1995;49:289\u2013308. https:\/\/doi.org\/10.1006\/BRLN.1995.1035.","journal-title":"Brain Lang"},{"key":"1017_CR76","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1093\/CERCOR\/6.2.260","volume":"6","author":"JJ Hutsler","year":"1996","unstructured":"Hutsler JJ, Gazzaniga MS. Acetylcholinesterase staining in human auditory and language cortices: regional variation of structural features. Cereb Cortex. 1996;6:260\u201370. https:\/\/doi.org\/10.1093\/CERCOR\/6.2.260.","journal-title":"Cereb Cortex"},{"key":"1017_CR77","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/S00429-021-02357-X","volume":"227","author":"T Sprung-Much","year":"2022","unstructured":"Sprung-Much T, Eichert N, Nolan E, Petrides M. Broca\u2019s area and the search for anatomical asymmetry: commentary and perspectives. Brain Struct Funct. 2022;227:441\u20139. https:\/\/doi.org\/10.1007\/S00429-021-02357-X.","journal-title":"Brain Struct Funct"},{"key":"1017_CR78","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1212\/WNL.31.7.799","volume":"31","author":"L Amaducci","year":"1981","unstructured":"Amaducci L, Sorbi S, Albanese A, Gainotti G. Choline acetyltransferase (ChAT) activity differs in right and left human temporal lobes. Neurology. 1981;31:799\u2013805. https:\/\/doi.org\/10.1212\/WNL.31.7.799.","journal-title":"Neurology"},{"key":"1017_CR79","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/0306-4522(83)90108-2","volume":"10","author":"MM Mesulam","year":"1983","unstructured":"Mesulam MM, Mufson EJ, Wainer BH, Levey AI. Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (Ch1\u2013Ch6). Neuroscience. 1983;10:1185\u2013201. https:\/\/doi.org\/10.1016\/0306-4522(83)90108-2.","journal-title":"Neuroscience"},{"key":"1017_CR80","doi-asserted-by":"publisher","first-page":"14792","DOI":"10.1073\/PNAS.94.26.14792","volume":"94","author":"SL Thompson-Schill","year":"1997","unstructured":"Thompson-Schill SL, D\u2019Esposito M, Aguirre GK, Farah MJ. Role of left inferior prefrontal cortex in retrieval of semantic knowledge: a reevaluation. Proc Natl Acad Sci USA. 1997;94:14792\u20137. https:\/\/doi.org\/10.1073\/PNAS.94.26.14792.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1017_CR81","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/J.CORTEX.2015.03.004","volume":"67","author":"DY Harvey","year":"2015","unstructured":"Harvey DY, Schnur TT. Distinct loci of lexical and semantic access deficits in aphasia: evidence from voxel-based lesion-symptom mapping and diffusion tensor imaging. Cortex. 2015;67:37\u201358. https:\/\/doi.org\/10.1016\/J.CORTEX.2015.03.004.","journal-title":"Cortex"},{"key":"1017_CR82","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1093\/BRAIN\/AWAB377","volume":"145","author":"JD Stefaniak","year":"2022","unstructured":"Stefaniak JD, Geranmayeh F, Lambon Ralph MA. The multidimensional nature of aphasia recovery post-stroke. Brain. 2022;145:1354\u201367. https:\/\/doi.org\/10.1093\/BRAIN\/AWAB377.","journal-title":"Brain"},{"key":"1017_CR83","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/J.TICS.2010.11.002","volume":"15","author":"M Husain","year":"2011","unstructured":"Husain M, Mehta MA. Cognitive enhancement by drugs in health and disease. Trends Cogn Sci. 2011;15:28\u201336. https:\/\/doi.org\/10.1016\/J.TICS.2010.11.002.","journal-title":"Trends Cogn Sci"},{"key":"1017_CR84","volume-title":"Disorders of human communication","author":"ML Albert","year":"1981","unstructured":"Albert ML, Goodglass H, Helm NA, et al. Clinical aspects of dysphasia. In: Arnold GE, Winckel FBDWBD, editors., et al., Disorders of human communication. Wien: Springer; 1981."},{"key":"1017_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/J.ARR.2022.101819","volume":"84","author":"S Lista","year":"2023","unstructured":"Lista S, Vergallo A, Teipel SJ, et al. Determinants of approved acetylcholinesterase inhibitor response outcomes in Alzheimer\u2019s disease: relevance for precision medicine in neurodegenerative diseases. Ageing Res Rev. 2023;84: 101819. https:\/\/doi.org\/10.1016\/J.ARR.2022.101819.","journal-title":"Ageing Res Rev"},{"key":"1017_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2017.00304","author":"ML Berthier","year":"2017","unstructured":"Berthier ML, De-Torres I, Paredes-Pacheco J, et al. Cholinergic potentiation and audiovisual repetition-imitation therapy improve speech production and communication deficits in a person with crossed aphasia by inducing structural plasticity in white matter tracts. Front Hum Neurosci. 2017. https:\/\/doi.org\/10.3389\/fnhum.2017.00304.","journal-title":"Front Hum Neurosci"},{"key":"1017_CR87","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1097\/01.JGP.0000221293.91312.D3","volume":"14","author":"JL Cummings","year":"2006","unstructured":"Cummings JL, McRae T, Zhang R. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. Am J Geriatr Psychiatry. 2006;14:605\u201312. https:\/\/doi.org\/10.1097\/01.JGP.0000221293.91312.D3.","journal-title":"Am J Geriatr Psychiatry"},{"key":"1017_CR88","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1159\/000149580","volume":"26","author":"EM Whyte","year":"2008","unstructured":"Whyte EM, Lenze EJ, Butters M, et al. An open-label pilot study of acetylcholinesterase inhibitors to promote functional recovery in elderly cognitively impaired stroke patients. Cerebrovasc Dis. 2008;26:317\u201321. https:\/\/doi.org\/10.1159\/000149580.","journal-title":"Cerebrovasc Dis"},{"key":"1017_CR89","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/CNS.12385","volume":"21","author":"MR Farlow","year":"2015","unstructured":"Farlow MR, Sadowsky CH, Velting DM, et al. Evaluating response to high-dose 13.3 mg\/24 h rivastigmine patch in patients with severe Alzheimer\u2019s disease. CNS Neurosci Ther. 2015;21:513\u20139. https:\/\/doi.org\/10.1111\/CNS.12385.","journal-title":"CNS Neurosci Ther"},{"key":"1017_CR90","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1017\/S1355617709090201","volume":"15","author":"LJ Gonzalez Rothi","year":"2009","unstructured":"Gonzalez Rothi LJ, Fuller R, Leon SA, et al. Errorless practice as a possible adjuvant to donepezil in Alzheimer\u2019s disease. J Int Neuropsychol Soc. 2009;15:311\u201322. https:\/\/doi.org\/10.1017\/S1355617709090201.","journal-title":"J Int Neuropsychol Soc"},{"key":"1017_CR91","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1191\/0269215505CR911OA","volume":"19","author":"CMC Bottino","year":"2005","unstructured":"Bottino CMC, Carvalho IAM, Alvarez AMMA, et al. Cognitive rehabilitation combined with drug treatment in Alzheimer\u2019s disease patients: a pilot study. Clin Rehabil. 2005;19:861\u20139. https:\/\/doi.org\/10.1191\/0269215505CR911OA.","journal-title":"Clin Rehabil"},{"key":"1017_CR92","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1044\/1092-4388(2004\/085)","volume":"47","author":"SB Chapman","year":"2004","unstructured":"Chapman SB, Weiner MF, Rackley A, et al. Effects of cognitive-communication stimulation for Alzheimer\u2019s disease patients treated with donepezil. J Speech Lang Hear Res. 2004;47:1149\u201363. https:\/\/doi.org\/10.1044\/1092-4388(2004\/085).","journal-title":"J Speech Lang Hear Res"},{"key":"1017_CR93","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1177\/1545968312440146","volume":"26","author":"N Jelcic","year":"2012","unstructured":"Jelcic N, Cagnin A, Meneghello F, et al. Effects of lexical-semantic treatment on memory in early Alzheimer disease: an observer-blinded randomized controlled trial. Neurorehabil Neural Repair. 2012;26:949\u201356. https:\/\/doi.org\/10.1177\/1545968312440146.","journal-title":"Neurorehabil Neural Repair"},{"key":"1017_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/J.TINS.2022.12.004","author":"H Hampel","year":"2023","unstructured":"Hampel H, Gao P, Cummings J, et al. The foundation and architecture of precision medicine in neurology and psychiatry. Trends Neurosci. 2023. https:\/\/doi.org\/10.1016\/J.TINS.2022.12.004.","journal-title":"Trends Neurosci"},{"key":"1017_CR95","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1177\/1535370217733426","volume":"243","author":"W Slikker","year":"2018","unstructured":"Slikker W. Biomarkers and their impact on precision medicine. Exp Biol Med (Maywood). 2018;243:211\u20132. https:\/\/doi.org\/10.1177\/1535370217733426.","journal-title":"Exp Biol Med (Maywood)"},{"key":"1017_CR96","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/NRG.2016.86","volume":"17","author":"EA Ashley","year":"2016","unstructured":"Ashley EA. Towards precision medicine. Nat Rev Genet. 2016;17:507\u201322. https:\/\/doi.org\/10.1038\/NRG.2016.86.","journal-title":"Nat Rev Genet"},{"key":"1017_CR97","doi-asserted-by":"publisher","DOI":"10.3389\/FPSYT.2019.00075","author":"MN Liu","year":"2019","unstructured":"Liu MN, Lau CI, Lin CP. Precision medicine for frontotemporal dementia. Front Psychiatry. 2019. https:\/\/doi.org\/10.3389\/FPSYT.2019.00075.","journal-title":"Front Psychiatry."},{"key":"1017_CR98","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1136\/JNNP-2016-314587","volume":"88","author":"JD Hinman","year":"2017","unstructured":"Hinman JD, Rost NS, Leung TW, et al. Principles of precision medicine in stroke. J Neurol Neurosurg Psychiatry. 2017;88:54\u201361. https:\/\/doi.org\/10.1136\/JNNP-2016-314587.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1017_CR99","doi-asserted-by":"publisher","DOI":"10.3389\/FNEUR.2019.00295","author":"S Kiran","year":"2019","unstructured":"Kiran S, Thompson CK. Neuroplasticity of language networks in aphasia: advances, updates, and future challenges. Front Neurol. 2019. https:\/\/doi.org\/10.3389\/FNEUR.2019.00295.","journal-title":"Front Neurol"},{"key":"1017_CR100","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.brs.2015.09.013","volume":"9","author":"R Bella","year":"2016","unstructured":"Bella R, Cantone M, Lanza G, et al. Cholinergic circuitry functioning in patients with vascular cognitive impairment\u2014no dementia. Brain Stimul. 2016;9:225\u201333. https:\/\/doi.org\/10.1016\/j.brs.2015.09.013.","journal-title":"Brain Stimul"},{"key":"1017_CR101","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1176\/JNP.12.1.77","volume":"12","author":"D Arciniegas","year":"2000","unstructured":"Arciniegas D, Olincy A, Topkoff J, et al. Impaired auditory gating and P50 nonsuppression following traumatic brain injury. J Neuropsychiatry Clin Neurosci. 2000;12:77\u201385. https:\/\/doi.org\/10.1176\/JNP.12.1.77.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"1017_CR102","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1176\/JNP.13.2.213","volume":"13","author":"DB Arciniegas","year":"2001","unstructured":"Arciniegas DB, Topkoff JL, Rojas DC, et al. Reduced hippocampal volume in association with p50 nonsuppression following traumatic brain injury. J Neuropsychiatry Clin Neurosci. 2001;13:213\u201321. https:\/\/doi.org\/10.1176\/JNP.13.2.213.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"Pt 6","key":"1017_CR103","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/BRAIN\/117.6.1377","volume":"117","author":"D Aarsland","year":"1994","unstructured":"Aarsland D, Larsen JP, Reinvang I, Aasland AM. Effects of cholinergic blockade on language in healthy young women: implications for the cholinergic hypothesis in dementia of the Alzheimer type. Brain. 1994;117(Pt 6):1377\u201384. https:\/\/doi.org\/10.1093\/BRAIN\/117.6.1377.","journal-title":"Brain"},{"key":"1017_CR104","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/ANA.410110208","volume":"11","author":"PA Fuld","year":"1982","unstructured":"Fuld PA, Katzman R, Davies P, Terry RD. Intrusions as a sign of Alzheimer dementia: chemical and pathological verification. Ann Neurol. 1982;11:155\u20139. https:\/\/doi.org\/10.1002\/ANA.410110208.","journal-title":"Ann Neurol"},{"key":"1017_CR105","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/J.BANDL.2005.07.013","volume":"97","author":"E Asp","year":"2006","unstructured":"Asp E, Song X, Rockwood K. Self-referential tags in the discourse of people with Alzheimer\u2019s disease. Brain Lan. 2006;97:41\u201352. https:\/\/doi.org\/10.1016\/J.BANDL.2005.07.013.","journal-title":"Brain Lan"},{"key":"1017_CR106","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/GPS.1486","volume":"21","author":"E Asp","year":"2006","unstructured":"Asp E, Cloutier F, Fay S, et al. Verbal repetition in patients with Alzheimer\u2019s disease who receive donepezil. Int J Geriatr Psychiatry. 2006;21:426\u201331. https:\/\/doi.org\/10.1002\/GPS.1486.","journal-title":"Int J Geriatr Psychiatry"},{"key":"1017_CR107","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1212\/01.WNL.0000258661.61577.B7","volume":"68","author":"K Rockwood","year":"2007","unstructured":"Rockwood K, Fay S, Jarrett P, Asp E. Effect of galantamine on verbal repetition in AD: a secondary analysis of the VISTA trial. Neurology. 2007;68:1116\u201321. https:\/\/doi.org\/10.1212\/01.WNL.0000258661.61577.B7.","journal-title":"Neurology"},{"key":"1017_CR108","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/J.JALZ.2005.09.004","volume":"1","author":"PJ Snyder","year":"2005","unstructured":"Snyder PJ, Bednar MM, Cromer JR, Maruff P. Reversal of scopolamine-induced deficits with a single dose of donepezil, an acetylcholinesterase inhibitor. Alzheimers Dement. 2005;1:126\u201335. https:\/\/doi.org\/10.1016\/J.JALZ.2005.09.004.","journal-title":"Alzheimers Dement"},{"key":"1017_CR109","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/J.NEUROPSYCHOLOGIA.2008.04.010","volume":"46","author":"E Thomas","year":"2008","unstructured":"Thomas E, Snyder PJ, Pietrzak RH, et al. Specific impairments in visuospatial working and short-term memory following low-dose scopolamine challenge in healthy older adults. Neuropsychologia. 2008;46:2476\u201384. https:\/\/doi.org\/10.1016\/J.NEUROPSYCHOLOGIA.2008.04.010.","journal-title":"Neuropsychologia"},{"key":"1017_CR110","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/J.IJPSYCHO.2009.01.011","volume":"73","author":"DF Fotiou","year":"2009","unstructured":"Fotiou DF, Stergiou V, Tsiptsios D, et al. Cholinergic deficiency in Alzheimer\u2019s and Parkinson\u2019s disease: evaluation with pupillometry. Int J Psychophysiol. 2009;73:143\u20139. https:\/\/doi.org\/10.1016\/J.IJPSYCHO.2009.01.011.","journal-title":"Int J Psychophysiol"},{"key":"1017_CR111","doi-asserted-by":"publisher","DOI":"10.1186\/S13195-020-00602-9","author":"M Marqui\u00e9","year":"2020","unstructured":"Marqui\u00e9 M, Valero S, Castilla-Marti M, et al. Association between retinal thickness and \u03b2-amyloid brain accumulation in individuals with subjective cognitive decline: Fundaci\u00f3 ACE Healthy Brain Initiative. Alzheimers Res Ther. 2020. https:\/\/doi.org\/10.1186\/S13195-020-00602-9.","journal-title":"Alzheimers Res Ther."},{"key":"1017_CR112","doi-asserted-by":"publisher","DOI":"10.3389\/FNEUR.2019.00360","author":"PS Chougule","year":"2019","unstructured":"Chougule PS, Najjar RP, Finkelstein MT, et al. Light-induced pupillary responses in Alzheimer\u2019s disease. Front Neurol. 2019. https:\/\/doi.org\/10.3389\/FNEUR.2019.00360.","journal-title":"Front Neurol"},{"key":"1017_CR113","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/S004010051031","volume":"97","author":"LFM Scinto","year":"1999","unstructured":"Scinto LFM, Wu CK, Firla KM, et al. Focal pathology in the Edinger\u2013Westphal nucleus explains pupillary hypersensitivity in Alzheimer\u2019s disease. Acta Neuropathol. 1999;97:557\u201364. https:\/\/doi.org\/10.1007\/S004010051031.","journal-title":"Acta Neuropathol"},{"key":"1017_CR114","doi-asserted-by":"publisher","first-page":"197","DOI":"10.5114\/FN.2014.43791","volume":"52","author":"IA Mavroudis","year":"2014","unstructured":"Mavroudis IA, Manani MG, Petrides F, et al. Dendritic and spinal alterations of neurons from Edinger\u2013Westphal nucleus in Alzheimer\u2019s disease. Folia Neuropathol. 2014;52:197\u2013204. https:\/\/doi.org\/10.5114\/FN.2014.43791.","journal-title":"Folia Neuropathol"},{"key":"1017_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/J.NEULET.2018.06.048","author":"JF Martin-Rodriguez","year":"2020","unstructured":"Martin-Rodriguez JF, Mir P. Short-afferent inhibition and cognitive impairment in Parkinson\u2019s disease: a quantitative review and challenges. Neurosci Lett. 2020. https:\/\/doi.org\/10.1016\/J.NEULET.2018.06.048.","journal-title":"Neurosci Lett"},{"issue":"Pt 2","key":"1017_CR116","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/J.1469-7793.2000.T01-1-00503.X","volume":"523","author":"H Tokimura","year":"2000","unstructured":"Tokimura H, Di Lazzaro V, Tokimura Y, et al. Short latency inhibition of human hand motor cortex by somatosensory input from the hand. J Physiol. 2000;523(Pt 2):503\u201313. https:\/\/doi.org\/10.1111\/J.1469-7793.2000.T01-1-00503.X.","journal-title":"J Physiol"},{"key":"1017_CR117","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-021-95573-8","author":"J Peter","year":"2021","unstructured":"Peter J, Mayer I, Kammer T, et al. The relationship between cholinergic system brain structure and function in healthy adults and patients with mild cognitive impairment. Sci Rep. 2021. https:\/\/doi.org\/10.1038\/S41598-021-95573-8.","journal-title":"Sci Rep"},{"key":"1017_CR118","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/ANA.26411","volume":"92","author":"A Benussi","year":"2022","unstructured":"Benussi A, Cantoni V, Grassi M, et al. Increasing brain gamma activity improves episodic memory and restores cholinergic dysfunction in Alzheimer\u2019s disease. Ann Neurol. 2022;92:322\u201334. https:\/\/doi.org\/10.1002\/ANA.26411.","journal-title":"Ann Neurol"},{"key":"1017_CR119","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/S00702-011-0725-3","volume":"119","author":"R Nardone","year":"2012","unstructured":"Nardone R, Bergmann J, Christova M, et al. Short latency afferent inhibition differs among the subtypes of mild cognitive impairment. J Neural Transm (Vienna). 2012;119:463\u201371. https:\/\/doi.org\/10.1007\/S00702-011-0725-3.","journal-title":"J Neural Transm (Vienna)"},{"key":"1017_CR120","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/J.NEULET.2011.05.007","volume":"498","author":"E Scelzo","year":"2011","unstructured":"Scelzo E, Giannicola G, Rosa M, et al. Increased short latency afferent inhibition after anodal transcranial direct current stimulation. Neurosci Lett. 2011;498:167\u201370. https:\/\/doi.org\/10.1016\/J.NEULET.2011.05.007.","journal-title":"Neurosci Lett"},{"key":"1017_CR121","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/J.BANDC.2015.12.005","volume":"102","author":"LA Jones","year":"2016","unstructured":"Jones LA, Hills PJ, Dick KM, et al. Cognitive mechanisms associated with auditory sensory gating. Brain Cogn. 2016;102:33\u201345. https:\/\/doi.org\/10.1016\/J.BANDC.2015.12.005.","journal-title":"Brain Cogn"},{"key":"1017_CR122","doi-asserted-by":"publisher","first-page":"5180","DOI":"10.1002\/HBM.23724","volume":"38","author":"S Josef Golubic","year":"2017","unstructured":"Josef Golubic S, Aine CJ, Stephen JM, et al. MEG biomarker of Alzheimer\u2019s disease: absence of a prefrontal generator during auditory sensory gating. Hum Brain Mapp. 2017;38:5180\u201394. https:\/\/doi.org\/10.1002\/HBM.23724.","journal-title":"Hum Brain Mapp"},{"key":"1017_CR123","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1176\/APPI.AJP.158.8.1319","volume":"158","author":"F Jessen","year":"2001","unstructured":"Jessen F, Kucharski C, Fries T, et al. Sensory gating deficit expressed by a disturbed suppression of the P50 event-related potential in patients with Alzheimer\u2019s disease. Am J Psychiatry. 2001;158:1319\u201321. https:\/\/doi.org\/10.1176\/APPI.AJP.158.8.1319.","journal-title":"Am J Psychiatry"},{"key":"1017_CR124","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1002\/CNE.24541","volume":"526","author":"RL Albin","year":"2018","unstructured":"Albin RL, Bohnen NI, Muller MLTM, et al. Regional vesicular acetylcholine transporter distribution in human brain: a [18 F]fluoroethoxybenzovesamicol positron emission tomography study. J Comp Neurol. 2018;526:2884\u201397. https:\/\/doi.org\/10.1002\/CNE.24541.","journal-title":"J Comp Neurol"},{"key":"1017_CR125","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/S40473-020-00221-6","volume":"7","author":"CE Craig","year":"2020","unstructured":"Craig CE, Ray NJ, M\u00fcller MLTM, Bohnen NI. New developments in cholinergic imaging in Alzheimer and Lewy body disorders. Curr Behav Neurosci Rep. 2020;7:278\u201386. https:\/\/doi.org\/10.1007\/S40473-020-00221-6.","journal-title":"Curr Behav Neurosci Rep"},{"key":"1017_CR126","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/1531-8249(200009)48:3<391::AID-ANA17>3.0.CO;2-H","volume":"48","author":"DE Kuhl","year":"2000","unstructured":"Kuhl DE, Minoshima S, Frey KA, et al. Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann Neurol. 2000;48:391\u20135. https:\/\/doi.org\/10.1002\/1531-8249(200009)48:3%3c391::AID-ANA17%3e3.0.CO;2-H.","journal-title":"Ann Neurol"},{"key":"1017_CR127","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/JLCR.3002","volume":"56","author":"T Kikuchi","year":"2013","unstructured":"Kikuchi T, Okamura T, Zhang MR, Irie T. PET probes for imaging brain acetylcholinesterase. J Labelled Comp Radiopharm. 2013;56:172\u20139. https:\/\/doi.org\/10.1002\/JLCR.3002.","journal-title":"J Labelled Comp Radiopharm."},{"key":"1017_CR128","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1038\/mp.2017.183","volume":"22","author":"M Aghourian","year":"2017","unstructured":"Aghourian M, Legault-Denis C, Soucy J-P, et al. Quantification of brain cholinergic denervation in Alzheimer\u2019s disease using PET imaging with [18F]-FEOBV. Mol Psychiatry. 2017;22:1531\u20138. https:\/\/doi.org\/10.1038\/mp.2017.183.","journal-title":"Mol Psychiatry"},{"key":"1017_CR129","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3233\/JAD-2012-111748","volume":"31","author":"A Marcone","year":"2012","unstructured":"Marcone A, Garibotto V, Moresco RM, et al. [11C]-MP4A PET cholinergic measurements in amnestic mild cognitive impairment, probable Alzheimer\u2019s disease, and dementia with Lewy bodies: a Bayesian method and voxel-based analysis. J Alzheimers Dis. 2012;31:387\u201399. https:\/\/doi.org\/10.3233\/JAD-2012-111748.","journal-title":"J Alzheimers Dis"},{"key":"1017_CR130","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/S0969-8051(98)00045-6","volume":"25","author":"SE Snyder","year":"1999","unstructured":"Snyder SE, Tluczek L, Jewett DM, et al. Synthesis of 1-[11 C]methylpiperidin-4-yl propionate ([11 C]PMP) for in vivo measurements of acetylcholinesterase activity. Nucl Med Biol. 1999;25:751\u20134.","journal-title":"Nucl Med Biol"},{"key":"1017_CR131","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1093\/BRAIN\/AWY099","volume":"141","author":"O Sabri","year":"2018","unstructured":"Sabri O, Meyer PM, Gr\u00e4f S, et al. Cognitive correlates of \u03b14\u03b22 nicotinic acetylcholine receptors in mild Alzheimer\u2019s dementia. Brain. 2018;141:1840\u201354. https:\/\/doi.org\/10.1093\/BRAIN\/AWY099.","journal-title":"Brain"},{"key":"1017_CR132","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/S00259-020-05029-W","volume":"48","author":"S Tiepolt","year":"2021","unstructured":"Tiepolt S, Becker GA, Wilke S, et al. (+)-[18F]Flubatine as a novel \u03b14\u03b22 nicotinic acetylcholine receptor PET ligand-results of the first-in-human brain imaging application in patients with \u03b2-amyloid PET-confirmed Alzheimer\u2019s disease and healthy controls. Eur J Nucl Med Mol Imaging. 2021;48:731\u201346. https:\/\/doi.org\/10.1007\/S00259-020-05029-W.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1017_CR133","doi-asserted-by":"publisher","DOI":"10.1186\/S13195-021-00954-W","author":"DL Sultzer","year":"2022","unstructured":"Sultzer DL, Lim AC, Gordon HL, et al. Cholinergic receptor binding in unimpaired older adults, mild cognitive impairment, and Alzheimer\u2019s disease dementia. Alzheimers Res Ther. 2022. https:\/\/doi.org\/10.1186\/S13195-021-00954-W.","journal-title":"Alzheimers Res Ther."},{"key":"1017_CR134","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/00004714-200212000-00012","volume":"22","author":"V Kaasinen","year":"2002","unstructured":"Kaasinen V, N\u00e5gren K, J\u00e4rvenp\u00e4\u00e4 T, et al. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer\u2019s disease. J Clin Psychopharmacol. 2002;22:615\u201320. https:\/\/doi.org\/10.1097\/00004714-200212000-00012.","journal-title":"J Clin Psychopharmacol"},{"key":"1017_CR135","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/J.1365-2125.2007.03063.X","volume":"65","author":"N Okamura","year":"2008","unstructured":"Okamura N, Funaki Y, Tashiro M, et al. In vivo visualization of donepezil binding in the brain of patients with Alzheimer\u2019s disease. Br J Clin Pharmacol. 2008;65:472\u20139. https:\/\/doi.org\/10.1111\/J.1365-2125.2007.03063.X.","journal-title":"Br J Clin Pharmacol"},{"key":"1017_CR136","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/J.NEUROIMAGE.2009.03.006","volume":"46","author":"K Hiraoka","year":"2009","unstructured":"Hiraoka K, Okamura N, Funaki Y, et al. Quantitative analysis of donepezil binding to acetylcholinesterase using positron emission tomography and [5-11C-methoxy]donepezil. Neuroimage. 2009;46:616\u201323. https:\/\/doi.org\/10.1016\/J.NEUROIMAGE.2009.03.006.","journal-title":"Neuroimage"},{"key":"1017_CR137","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/WAD.0B013E3182222BC0","volume":"26","author":"M Kasuya","year":"2012","unstructured":"Kasuya M, Meguro K, Okamura N, et al. Greater responsiveness to donepezil in Alzheimer patients with higher levels of acetylcholinesterase based on attention task scores and a donepezil PET study. Alzheimer Dis Assoc Disord. 2012;26:113\u20138. https:\/\/doi.org\/10.1097\/WAD.0B013E3182222BC0.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"1017_CR138","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.2147\/CIA.S39959","volume":"8","author":"SH Ferris","year":"2013","unstructured":"Ferris SH, Farlow M. Language impairment in Alzheimer\u2019s disease and benefits of acetylcholinesterase inhibitors. Clin Interv Aging. 2013;8:1007\u201314. https:\/\/doi.org\/10.2147\/CIA.S39959.","journal-title":"Clin Interv Aging"},{"key":"1017_CR139","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1212\/01.WNL.0000242626.69666.E2","volume":"67","author":"ML Berthier","year":"2006","unstructured":"Berthier ML, Green C, Higueras C, et al. A randomized, placebo-controlled study of donepezil in poststroke aphasia. Neurology. 2006;67:1687\u20139. https:\/\/doi.org\/10.1212\/01.WNL.0000242626.69666.E2.","journal-title":"Neurology"},{"key":"1017_CR140","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/J.CORTEX.2016.07.004","volume":"83","author":"S Teipel","year":"2016","unstructured":"Teipel S, Raiser T, Riedl L, et al. Atrophy and structural covariance of the cholinergic basal forebrain in primary progressive aphasia. Cortex. 2016;83:124\u201335. https:\/\/doi.org\/10.1016\/J.CORTEX.2016.07.004.","journal-title":"Cortex"},{"key":"1017_CR141","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1017\/CJN.2019.6","volume":"6","author":"H Hamodat","year":"2019","unstructured":"Hamodat H, Fisk JD, Darvesh S. Cholinergic neurons in nucleus subputaminalis in primary progressive aphasia. Can J Neurol Sci. 2019;6:174\u201383. https:\/\/doi.org\/10.1017\/CJN.2019.6.","journal-title":"Can J Neurol Sci"},{"key":"1017_CR142","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1093\/CERCOR\/BHZ224","volume":"30","author":"JL Cantero","year":"2020","unstructured":"Cantero JL, Atienza M, Lage C, et al. Atrophy of basal forebrain initiates with tau pathology in individuals at risk for Alzheimer\u2019s disease. Cereb Cortex. 2020;30:2083\u201398. https:\/\/doi.org\/10.1093\/CERCOR\/BHZ224.","journal-title":"Cereb Cortex"},{"key":"1017_CR143","doi-asserted-by":"publisher","first-page":"e1631","DOI":"10.4088\/JCP.15M10413","volume":"77","author":"E Cavedo","year":"2016","unstructured":"Cavedo E, Dubois B, Colliot O, et al. Reduced regional cortical thickness rate of change in donepezil-treated subjects with suspected prodromal Alzheimer\u2019s disease. J Clin Psychiatry. 2016;77:e1631\u20138. https:\/\/doi.org\/10.4088\/JCP.15M10413.","journal-title":"J Clin Psychiatry"},{"key":"1017_CR144","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024126","author":"JH Balsters","year":"2011","unstructured":"Balsters JH, O\u2019Connell RG, Martin MP, et al. Donepezil impairs memory in healthy older subjects: behavioural, EEG and simultaneous EEG\/fMRI biomarkers. PLoS ONE. 2011. https:\/\/doi.org\/10.1371\/journal.pone.0024126.","journal-title":"PLoS ONE"},{"key":"1017_CR145","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1007\/S00213-021-05923-7","volume":"238","author":"P P\u00e9ran","year":"2021","unstructured":"P\u00e9ran P, Salabert AS, Dondaine T, et al. Functional connectivity and cognitive changes after donepezil treatment in healthy participants. Psychopharmacology. 2021;238:3071\u201382. https:\/\/doi.org\/10.1007\/S00213-021-05923-7.","journal-title":"Psychopharmacology"},{"key":"1017_CR146","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/S10548-017-0608-5","volume":"31","author":"J Wirsich","year":"2018","unstructured":"Wirsich J, Rey M, Guye M, et al. Brain networks are independently modulated by donepezil, sleep, and sleep deprivation. Brain Topogr. 2018;31:380\u201391. https:\/\/doi.org\/10.1007\/S10548-017-0608-5.","journal-title":"Brain Topogr"},{"key":"1017_CR147","doi-asserted-by":"publisher","first-page":"11369","DOI":"10.1523\/JNEUROSCI.4045-08.2008","volume":"28","author":"LYM Chuah","year":"2008","unstructured":"Chuah LYM, Chee MWL. Cholinergic augmentation modulates visual task performance in sleep-deprived young adults. J Neurosci. 2008;28:11369\u201377. https:\/\/doi.org\/10.1523\/JNEUROSCI.4045-08.2008.","journal-title":"J Neurosci"},{"key":"1017_CR148","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/SLEEP\/32.8.999","volume":"32","author":"LYM Chuah","year":"2009","unstructured":"Chuah LYM, Chong DL, Chen AK, et al. Donepezil improves episodic memory in young individuals vulnerable to the effects of sleep deprivation. Sleep. 2009;32:999\u20131010. https:\/\/doi.org\/10.1093\/SLEEP\/32.8.999.","journal-title":"Sleep"},{"key":"1017_CR149","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/JCP.0B013E3182825BFD","volume":"33","author":"C Sol\u00e9-Padull\u00e9s","year":"2013","unstructured":"Sol\u00e9-Padull\u00e9s C, Bartr\u00e9s-Faz D, Llad\u00f3 A, et al. Donepezil treatment stabilizes functional connectivity during resting state and brain activity during memory encoding in Alzheimer\u2019s disease. J Clin Psychopharmacol. 2013;33:199\u2013205. https:\/\/doi.org\/10.1097\/JCP.0B013E3182825BFD.","journal-title":"J Clin Psychopharmacol"},{"key":"1017_CR150","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/JMRI.22662","volume":"34","author":"JS Goveas","year":"2011","unstructured":"Goveas JS, Xie C, Ward BD, et al. Recovery of hippocampal network connectivity correlates with cognitive improvement in mild Alzheimer\u2019s disease patients treated with donepezil assessed by resting-state fMRI. J Magn Reson Imaging. 2011;34:764\u201373. https:\/\/doi.org\/10.1002\/JMRI.22662.","journal-title":"J Magn Reson Imaging"},{"key":"1017_CR151","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1159\/000450546","volume":"6","author":"L Griffanti","year":"2016","unstructured":"Griffanti L, Wilcock GK, Voets N, et al. Donepezil enhances frontal functional connectivity in Alzheimer\u2019s disease: a pilot study. Dement Geriatr Cogn Dis Extra. 2016;6:518\u201328. https:\/\/doi.org\/10.1159\/000450546.","journal-title":"Dement Geriatr Cogn Dis Extra."},{"key":"1017_CR152","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/WAD.0B013E318299D096","volume":"28","author":"L Wang","year":"2014","unstructured":"Wang L, Day J, Roe CM, et al. The effect of APOE \u03b54 allele on cholinesterase inhibitors in patients with Alzheimer disease: evaluation of the feasibility of resting state functional connectivity magnetic resonance imaging. Alzheimer Dis Assoc Disord. 2014;28:122\u20137. https:\/\/doi.org\/10.1097\/WAD.0B013E318299D096.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"1017_CR153","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/J.NEUROIMAGE.2011.12.077","volume":"60","author":"W Li","year":"2012","unstructured":"Li W, Antuono PG, Xie C, et al. Changes in regional cerebral blood flow and functional connectivity in the cholinergic pathway associated with cognitive performance in subjects with mild Alzheimer\u2019s disease after 12-week donepezil treatment. Neuroimage. 2012;60:1083\u201391. https:\/\/doi.org\/10.1016\/J.NEUROIMAGE.2011.12.077.","journal-title":"Neuroimage"},{"key":"1017_CR154","doi-asserted-by":"publisher","DOI":"10.1016\/J.NEUROPHARM.2020.108352","author":"G Marucci","year":"2021","unstructured":"Marucci G, Buccioni M, Ben DD, et al. Efficacy of acetylcholinesterase inhibitors in Alzheimer\u2019s disease. Neuropharmacology. 2021. https:\/\/doi.org\/10.1016\/J.NEUROPHARM.2020.108352.","journal-title":"Neuropharmacology"},{"key":"1017_CR155","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/S40266-022-00944-Z","volume":"39","author":"PP Masurkar","year":"2022","unstructured":"Masurkar PP, Chatterjee S, Sherer JT, et al. Risk of serious adverse events associated with individual cholinesterase inhibitors use in older adults with dementia: a population-based cohort study. Drugs Aging. 2022;39:453\u201365. https:\/\/doi.org\/10.1007\/S40266-022-00944-Z.","journal-title":"Drugs Aging"},{"key":"1017_CR156","doi-asserted-by":"publisher","first-page":"927","DOI":"10.2147\/TCRM.S323387","volume":"17","author":"S Ruangritchankul","year":"2021","unstructured":"Ruangritchankul S, Chantharit P, Srisuma S, Gray LC. Adverse drug reactions of acetylcholinesterase inhibitors in older people living with dementia: a comprehensive literature review. Ther Clin Risk Manag. 2021;17:927\u201349. https:\/\/doi.org\/10.2147\/TCRM.S323387.","journal-title":"Ther Clin Risk Manag"},{"key":"1017_CR157","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000335895","volume":"68","author":"ST Engelter","year":"2012","unstructured":"Engelter ST, Urscheler N, Baronti F, et al. Frequency and determinants of using pharmacological enhancement in the clinical practice of in-hospital stroke rehabilitation. Eur Neurol. 2012;68:28\u201333. https:\/\/doi.org\/10.1159\/000335895.","journal-title":"Eur Neurol"},{"key":"1017_CR158","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/J.JAMDA.2017.03.008","volume":"18","author":"JP Michel","year":"2017","unstructured":"Michel JP, Sadana R. \u201cHealthy aging\u201d concepts and measures. J Am Med Dir Assoc. 2017;18:460\u20134. https:\/\/doi.org\/10.1016\/J.JAMDA.2017.03.008.","journal-title":"J Am Med Dir Assoc"},{"key":"1017_CR159","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/J.JALZ.2018.07.219","volume":"16","author":"Y Stern","year":"2020","unstructured":"Stern Y, Arenaza-Urquijo EM, Bartr\u00e9s-Faz D, et al. Whitepaper: defining and investigating cognitive reserve, brain reserve, and brain maintenance. Alzheimers Dement. 2020;16:1305\u201311. https:\/\/doi.org\/10.1016\/J.JALZ.2018.07.219.","journal-title":"Alzheimers Dement"},{"key":"1017_CR160","doi-asserted-by":"publisher","DOI":"10.1038\/NCOMMS13249","author":"TW Schmitz","year":"2016","unstructured":"Schmitz TW, Nathan Spreng R. Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer\u2019s pathology. Nat Commun. 2016. https:\/\/doi.org\/10.1038\/NCOMMS13249.","journal-title":"Nat Commun"},{"key":"1017_CR161","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1093\/BRAIN\/AWAC096","volume":"145","author":"E Giacobini","year":"2022","unstructured":"Giacobini E, Cuello AC, Fisher A. Reimagining cholinergic therapy for Alzheimer\u2019s disease. Brain. 2022;145:2250\u201375. https:\/\/doi.org\/10.1093\/BRAIN\/AWAC096.","journal-title":"Brain"},{"key":"1017_CR162","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s40266-019-00743-z","volume":"37","author":"E Attoh-Mensah","year":"2020","unstructured":"Attoh-Mensah E, Loggia G, Schumann-Bard P, et al. Adverse effects of anticholinergic drugs on cognition and mobility: cutoff for impairment in a cross-sectional study in young-old and old-old adults. Drugs Aging. 2020;37:301\u201310. https:\/\/doi.org\/10.1007\/s40266-019-00743-z.","journal-title":"Drugs Aging"},{"key":"1017_CR163","doi-asserted-by":"publisher","first-page":"E2295","DOI":"10.1212\/WNL.0000000000010643","volume":"95","author":"AJ Weigand","year":"2020","unstructured":"Weigand AJ, Bondi MW, Thomas KR, et al. Association of anticholinergic medications and AD biomarkers with incidence of MCI among cognitively normal older adults. Neurology. 2020;95:E2295\u2013304. https:\/\/doi.org\/10.1212\/WNL.0000000000010643.","journal-title":"Neurology"},{"key":"1017_CR164","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/S40266-016-0400-3","volume":"33","author":"S Swami","year":"2016","unstructured":"Swami S, Cohen RA, Kairalla JA, Manini TM. Anticholinergic drug use and risk to cognitive performance in older adults with questionable cognitive impairment: a cross-sectional analysis. Drugs Aging. 2016;33:809\u201318. https:\/\/doi.org\/10.1007\/S40266-016-0400-3.","journal-title":"Drugs Aging"},{"key":"1017_CR165","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1037\/NEU0000713","volume":"35","author":"BG Collin","year":"2021","unstructured":"Collin BG, Raju D, Katsikas S. The cognitive effects of anticholinergic drugs on apolipoprotein \u03b54 carriers and noncarriers in the Wisconsin Registry for Alzheimer\u2019s Prevention study. Neuropsychology. 2021;35:220\u201331. https:\/\/doi.org\/10.1037\/NEU0000713.","journal-title":"Neuropsychology"},{"key":"1017_CR166","doi-asserted-by":"publisher","DOI":"10.3389\/FNAGI.2022.959405","author":"M Rafiq","year":"2022","unstructured":"Rafiq M, Jucla M, Guerrier L, et al. The functional connectivity of language network across the life span: disentangling the effects of typical aging from Alzheimer\u2019s disease. Front Aging Neurosci. 2022. https:\/\/doi.org\/10.3389\/FNAGI.2022.959405.","journal-title":"Front Aging Neurosci."},{"key":"1017_CR167","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1162\/JOCN.2007.19.12.2060","volume":"19","author":"MA Shafto","year":"2007","unstructured":"Shafto MA, Burke DM, Stamatakis EA, et al. On the tip-of-the-tongue: neural correlates of increased word-finding failures in normal aging. J Cogn Neurosci. 2007;19:2060\u201370. https:\/\/doi.org\/10.1162\/JOCN.2007.19.12.2060.","journal-title":"J Cogn Neurosci"},{"key":"1017_CR168","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/J.NEUROPSYCHOLOGIA.2018.11.017","volume":"124","author":"H Zhang","year":"2019","unstructured":"Zhang H, Eppes A, Diaz MT. Task difficulty modulates age-related differences in the behavioral and neural bases of language production. Neuropsychologia. 2019;124:254\u201373. https:\/\/doi.org\/10.1016\/J.NEUROPSYCHOLOGIA.2018.11.017.","journal-title":"Neuropsychologia"},{"key":"1017_CR169","doi-asserted-by":"publisher","DOI":"10.3389\/FNAGI.2022.931536","author":"J Lee","year":"2022","unstructured":"Lee J, Kim HJ. Normal aging induces changes in the brain and neurodegeneration progress: review of the structural, biochemical, metabolic, cellular, and molecular changes. Front Aging Neurosci. 2022. https:\/\/doi.org\/10.3389\/FNAGI.2022.931536.","journal-title":"Front Aging Neurosci."},{"key":"1017_CR170","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2174\/1871524919666190320102834","volume":"19","author":"YN Utkin","year":"2019","unstructured":"Utkin YN. Aging affects nicotinic acetylcholine receptors in brain. Cent Nerv Syst Agents Med Chem. 2019;19:119\u201324. https:\/\/doi.org\/10.2174\/1871524919666190320102834.","journal-title":"Cent Nerv Syst Agents Med Chem"},{"key":"1017_CR171","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13195-021-00844-1","volume":"13","author":"A Brioschi Guevara","year":"2021","unstructured":"Brioschi Guevara A, Bieler M, Altomare D, et al. Protocols for cognitive enhancement: a user manual for Brain Health Services\u2014part 5 of 6. Alzheimers Res Ther. 2021;13:172.","journal-title":"Alzheimers Res Ther."},{"key":"1017_CR172","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1093\/CERCOR\/BHM155","volume":"18","author":"SW Davis","year":"2008","unstructured":"Davis SW, Dennis NA, Daselaar SM, et al. Que PASA? The posterior-anterior shift in aging. Cereb Cortex. 2008;18:1201\u20139. https:\/\/doi.org\/10.1093\/CERCOR\/BHM155.","journal-title":"Cereb Cortex"},{"key":"1017_CR173","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/J.1467-8721.2008.00570.X\/FORMAT\/EPUB","volume":"17","author":"PA Reuter-Lorenz","year":"2008","unstructured":"Reuter-Lorenz PA, Cappell KA. Neurocognitive aging and the compensation hypothesis. Curr Dir Psychol Sci. 2008;17:177\u201382. https:\/\/doi.org\/10.1111\/J.1467-8721.2008.00570.X\/FORMAT\/EPUB.","journal-title":"Curr Dir Psychol Sci"},{"key":"1017_CR174","doi-asserted-by":"publisher","DOI":"10.3389\/FNAGI.2021.644611","author":"R Mohanty","year":"2021","unstructured":"Mohanty R, Gonzalez-Burgos L, Diaz-Flores L, et al. Functional connectivity and compensation of phonemic fluency in aging. Front Aging Neurosci. 2021. https:\/\/doi.org\/10.3389\/FNAGI.2021.644611.","journal-title":"Front Aging Neurosci."},{"key":"1017_CR175","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/J.NEURAD.2011.05.005","volume":"39","author":"C Destrieux","year":"2012","unstructured":"Destrieux C, Hommet C, Domengie F, et al. Influence of age on the dynamics of fMRI activations during a semantic fluency task. J Neuroradiol. 2012;39:158\u201366. https:\/\/doi.org\/10.1016\/J.NEURAD.2011.05.005.","journal-title":"J Neuroradiol"},{"key":"1017_CR176","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1111\/EJN.12252","volume":"37","author":"J Ansado","year":"2013","unstructured":"Ansado J, Marsolais Y, Methqal I, et al. The adaptive aging brain: evidence from the preservation of communication abilities with age. Eur J Neurosci. 2013;37:1887\u201395. https:\/\/doi.org\/10.1111\/EJN.12252.","journal-title":"Eur J Neurosci"},{"key":"1017_CR177","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/J.BANDL.2011.09.008","volume":"121","author":"LC Scherer","year":"2012","unstructured":"Scherer LC, Fonseca RP, Giroux F, et al. Neurofunctional (re)organization underlying narrative discourse processing in aging: evidence from fNIRS. Brain Lang. 2012;121:174\u201384. https:\/\/doi.org\/10.1016\/J.BANDL.2011.09.008.","journal-title":"Brain Lang"},{"key":"1017_CR178","doi-asserted-by":"publisher","DOI":"10.3389\/FNAGI.2018.00069","author":"CO Martin","year":"2018","unstructured":"Martin CO, Pontbriand-Drolet S, Daoust V, et al. Narrative discourse in young and older adults: behavioral and NIRS analyses. Front Aging Neurosci. 2018. https:\/\/doi.org\/10.3389\/FNAGI.2018.00069.","journal-title":"Front Aging Neurosci."},{"key":"1017_CR179","doi-asserted-by":"publisher","DOI":"10.3389\/FPSYG.2015.00663","author":"R Sala-Llonch","year":"2015","unstructured":"Sala-Llonch R, Bartr\u00e9s-Faz D, Junqu\u00e9 C. Reorganization of brain networks in aging: a review of functional connectivity studies. Front Psychol. 2015. https:\/\/doi.org\/10.3389\/FPSYG.2015.00663.","journal-title":"Front Psychol"},{"key":"1017_CR180","doi-asserted-by":"publisher","DOI":"10.3389\/FPSYG.2019.01974","author":"C Maruta","year":"2019","unstructured":"Maruta C, Martins IP. May subjective language complaints predict future language decline in community-dwelling subjects? Front Psychol. 2019. https:\/\/doi.org\/10.3389\/FPSYG.2019.01974.","journal-title":"Front Psychol"},{"key":"1017_CR181","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1177\/0271678X21990980","volume":"41","author":"S Hilal","year":"2021","unstructured":"Hilal S, Liu S, Wong TY, et al. White matter network damage mediates association between cerebrovascular disease and cognition. J Cereb Blood Flow Metab. 2021;41:1858\u201372. https:\/\/doi.org\/10.1177\/0271678X21990980.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1017_CR182","doi-asserted-by":"publisher","DOI":"10.1016\/J.LANEPE.2022.100576","author":"GB Frisoni","year":"2023","unstructured":"Frisoni GB, Altomare D, Ribaldi F, et al. Dementia prevention in memory clinics: recommendations from the European Task Force for Brain Health Services. Lancet Reg Health Europe. 2023. https:\/\/doi.org\/10.1016\/J.LANEPE.2022.100576.","journal-title":"Lancet Reg Health Europe."},{"key":"1017_CR183","doi-asserted-by":"publisher","DOI":"10.1093\/GERONB\/63.5.P288","author":"JA Yesavage","year":"2008","unstructured":"Yesavage JA, Friedman L, Ashford JW, et al. Acetylcholinesterase inhibitor in combination with cognitive training in older adults. J Gerontol B Psychol Sci Soc Sci. 2008. https:\/\/doi.org\/10.1093\/GERONB\/63.5.P288.","journal-title":"J Gerontol B Psychol Sci Soc Sci"},{"key":"1017_CR184","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/J.PSYCHRES.2015.07.006","volume":"229","author":"G Fond","year":"2015","unstructured":"Fond G, Micoulaud-Franchi JA, Brunel L, et al. Innovative mechanisms of action for pharmaceutical cognitive enhancement: a systematic review. Psychiatry Res. 2015;229:12\u201320. https:\/\/doi.org\/10.1016\/J.PSYCHRES.2015.07.006.","journal-title":"Psychiatry Res"},{"issue":"Pt 3","key":"1017_CR185","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/BRAIN\/123.3.484","volume":"123","author":"CJ Galton","year":"2000","unstructured":"Galton CJ, Patterson K, Xuereb JH, Hodges JR. Atypical and typical presentations of Alzheimer\u2019s disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. Brain. 2000;123(Pt 3):484\u201398. https:\/\/doi.org\/10.1093\/BRAIN\/123.3.484.","journal-title":"Brain"},{"key":"1017_CR186","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/BRAIN\/AWS076","volume":"135","author":"T Gefen","year":"2012","unstructured":"Gefen T, Gasho K, Rademaker A, et al. Clinically concordant variations of Alzheimer pathology in aphasic versus amnestic dementia. Brain. 2012;135:1554\u201365. https:\/\/doi.org\/10.1093\/BRAIN\/AWS076.","journal-title":"Brain"},{"key":"1017_CR187","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/01.WNN.0000213912.87642.3D","volume":"19","author":"S Cosentino","year":"2006","unstructured":"Cosentino S, Scarmeas N, Albert SM, Stern Y. Verbal fluency predicts mortality in Alzheimer disease. Cogn Behav Neurol. 2006;19:123\u20139. https:\/\/doi.org\/10.1097\/01.WNN.0000213912.87642.3D.","journal-title":"Cogn Behav Neurol"},{"key":"1017_CR188","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.2147\/CIA.S89714","volume":"10","author":"B Klimova","year":"2015","unstructured":"Klimova B, Maresova P, Valis M, et al. Alzheimer\u2019s disease and language impairments: social intervention and medical treatment. Clin Interv Aging. 2015;10:1401\u20138. https:\/\/doi.org\/10.2147\/CIA.S89714.","journal-title":"Clin Interv Aging"},{"key":"1017_CR189","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1017\/S031716710003701X","volume":"13","author":"A Kertesz","year":"1986","unstructured":"Kertesz A, Appell J, Fisman M. The dissolution of language in Alzheimer\u2019s disease. Can J Neurol Sci. 1986;13:415\u20138. https:\/\/doi.org\/10.1017\/S031716710003701X.","journal-title":"Can J Neurol Sci"},{"key":"1017_CR190","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1001\/ARCHNEUR.1993.00540090038008","volume":"50","author":"BH Price","year":"1993","unstructured":"Price BH, Weintraub S, Geula C, et al. Neuropsychological patterns and language deficits in 20 consecutive cases of autopsy-confirmed Alzheimer\u2019s disease. Arch Neurol. 1993;50:931\u20137. https:\/\/doi.org\/10.1001\/ARCHNEUR.1993.00540090038008.","journal-title":"Arch Neurol"},{"key":"1017_CR191","doi-asserted-by":"publisher","DOI":"10.1186\/ALZRT229","author":"S Ferris","year":"2013","unstructured":"Ferris S, Karantzoulis S, Somogyi M, Meng X. Rivastigmine in moderately severe-to-severe Alzheimer\u2019s disease: Severe Impairment Battery factor analysis. Alzheimers Res Ther. 2013. https:\/\/doi.org\/10.1186\/ALZRT229.","journal-title":"Alzheimers Res Ther."},{"key":"1017_CR192","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1474-4422(05)70219-2","volume":"4","author":"I McKeith","year":"2005","unstructured":"McKeith I, Cummings J. Behavioural changes and psychological symptoms in dementia disorders. Lancet Neurol. 2005;4:735\u201342. https:\/\/doi.org\/10.1016\/S1474-4422(05)70219-2.","journal-title":"Lancet Neurol"},{"key":"1017_CR193","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.3233\/JAD-160252","volume":"54","author":"KD Mueller","year":"2016","unstructured":"Mueller KD, Koscik RL, Turkstra LS, et al. Connected language in late middle-aged adults at risk for Alzheimer\u2019s disease. J Alzheimers Dis. 2016;54:1539\u201350. https:\/\/doi.org\/10.3233\/JAD-160252.","journal-title":"J Alzheimers Dis"},{"key":"1017_CR194","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1080\/13803395.2018.1446513","volume":"40","author":"KD Mueller","year":"2018","unstructured":"Mueller KD, Hermann B, Mecollari J, Turkstra LS. Connected speech and language in mild cognitive impairment and Alzheimer\u2019s disease: a review of picture description tasks. J Clin Exp Neuropsychol. 2018;40:917\u201339. https:\/\/doi.org\/10.1080\/13803395.2018.1446513.","journal-title":"J Clin Exp Neuropsychol"},{"key":"1017_CR195","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1093\/BRAIN\/AWT269","volume":"136","author":"S Ahmed","year":"2013","unstructured":"Ahmed S, Haigh AMF, de Jager CA, Garrard P. Connected speech as a marker of disease progression in autopsy-proven Alzheimer\u2019s disease. Brain. 2013;136:3727\u201337. https:\/\/doi.org\/10.1093\/BRAIN\/AWT269.","journal-title":"Brain"},{"issue":"Suppl 3","key":"1017_CR196","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3233\/JAD-140555","volume":"42","author":"V Rentoumi","year":"2014","unstructured":"Rentoumi V, Raoufian L, Ahmed S, et al. Features and machine learning classification of connected speech samples from patients with autopsy proven Alzheimer\u2019s disease with and without additional vascular pathology. J Alzheimers Dis. 2014;42(Suppl 3):S3-17. https:\/\/doi.org\/10.3233\/JAD-140555.","journal-title":"J Alzheimers Dis"},{"key":"1017_CR197","doi-asserted-by":"publisher","DOI":"10.1002\/DAD2.12276","author":"C Sanz","year":"2022","unstructured":"Sanz C, Carrillo F, Slachevsky A, et al. Automated text-level semantic markers of Alzheimer\u2019s disease. Alzheimers Dement (Amst). 2022. https:\/\/doi.org\/10.1002\/DAD2.12276.","journal-title":"Alzheimers Dement (Amst)."},{"key":"1017_CR198","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/J.CORTEX.2020.05.001","volume":"129","author":"N Clarke","year":"2020","unstructured":"Clarke N, Foltz P, Garrard P. How to do things with (thousands of) words: computational approaches to discourse analysis in Alzheimer\u2019s disease. Cortex. 2020;129:446\u201363. https:\/\/doi.org\/10.1016\/J.CORTEX.2020.05.001.","journal-title":"Cortex"},{"key":"1017_CR199","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3233\/JAD-150520","volume":"49","author":"KC Fraser","year":"2016","unstructured":"Fraser KC, Meltzer JA, Rudzicz F. Linguistic features identify Alzheimer\u2019s disease in narrative speech. J Alzheimers Dis. 2016;49:407\u201322. https:\/\/doi.org\/10.3233\/JAD-150520.","journal-title":"J Alzheimers Dis"},{"key":"1017_CR200","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.1044\/2021_JSLHR-20-00503","volume":"64","author":"JC Sherman","year":"2021","unstructured":"Sherman JC, Henderson CR, Flynn S, et al. Language decline characterizes amnestic mild cognitive impairment independent of cognitive decline. J Speech Lang Hear Res. 2021;64:4287\u2013307. https:\/\/doi.org\/10.1044\/2021_JSLHR-20-00503.","journal-title":"J Speech Lang Hear Res"},{"key":"1017_CR201","doi-asserted-by":"publisher","first-page":"611","DOI":"10.3233\/JAD-170826","volume":"62","author":"M Alegret","year":"2018","unstructured":"Alegret M, Peret\u00f3 M, P\u00e9rez A, et al. The role of verb fluency in the detection of early cognitive impairment in Alzheimer\u2019s disease. J Alzheimers Dis. 2018;62:611\u20139. https:\/\/doi.org\/10.3233\/JAD-170826.","journal-title":"J Alzheimers Dis"},{"key":"1017_CR202","doi-asserted-by":"publisher","DOI":"10.1186\/S13195-021-00848-X","author":"A Yeung","year":"2021","unstructured":"Yeung A, Iaboni A, Rochon E, et al. Correlating natural language processing and automated speech analysis with clinician assessment to quantify speech-language changes in mild cognitive impairment and Alzheimer\u2019s dementia. Alzheimers Res Ther. 2021. https:\/\/doi.org\/10.1186\/S13195-021-00848-X.","journal-title":"Alzheimers Res Ther."},{"key":"1017_CR203","doi-asserted-by":"publisher","DOI":"10.3389\/FNINS.2016.00205","author":"M Unzeta","year":"2016","unstructured":"Unzeta M, Esteban G, Bolea I, et al. Multi-target directed donepezil-like ligands for Alzheimer\u2019s disease. Front Neurosci. 2016. https:\/\/doi.org\/10.3389\/FNINS.2016.00205.","journal-title":"Front Neurosci"},{"key":"1017_CR204","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/NMD.0000000000000107","volume":"202","author":"J Song","year":"2014","unstructured":"Song J, Ahn IS, Kang HS, et al. Cognitive subdomain responses to galantamine in Alzheimer\u2019s disease. J Nerv Ment Dis. 2014;202:253\u20139. https:\/\/doi.org\/10.1097\/NMD.0000000000000107.","journal-title":"J Nerv Ment Dis"},{"key":"1017_CR205","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1017\/S1092852900020174","volume":"14","author":"ML Davis","year":"2009","unstructured":"Davis ML, Barrett AM. Selective benefit of donepezil on oral naming in Alzheimer\u2019s disease in men compared to women. CNS Spectr. 2009;14:175\u20136. https:\/\/doi.org\/10.1017\/S1092852900020174.","journal-title":"CNS Spectr"},{"key":"1017_CR206","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/S12603-009-0007-Z","volume":"13","author":"EG Visch-Brink","year":"2009","unstructured":"Visch-Brink EG, van Rhee-Temme W, Rietveld T, et al. Improvement of spontaneous speech in early stage Alzheimer\u2019s with rivastigmine. J Nutr Health Aging. 2009;13:34\u20138. https:\/\/doi.org\/10.1007\/S12603-009-0007-Z.","journal-title":"J Nutr Health Aging"},{"key":"1017_CR207","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology. 1984;34:939\u201344. https:\/\/doi.org\/10.1212\/WNL.34.7.939.","journal-title":"Neurology"},{"key":"1017_CR208","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1159\/000106895","volume":"7","author":"SL Rogers","year":"1996","unstructured":"Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer\u2019s disease: results of a US multicentre, randomized, double-blind, placebo-controlledtTrial. The Donepezil Study Group. Dementia. 1996;7:293\u2013303. https:\/\/doi.org\/10.1159\/000106895.","journal-title":"Dementia"},{"key":"1017_CR209","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1001\/ARCHINTE.158.9.1021","volume":"158","author":"SL Rogers","year":"1998","unstructured":"Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med. 1998;158:1021\u201331. https:\/\/doi.org\/10.1001\/ARCHINTE.158.9.1021.","journal-title":"Arch Intern Med"},{"key":"1017_CR210","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1212\/WNL.50.1.136","volume":"50","author":"SL Rogers","year":"1998","unstructured":"Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer\u2019s disease. Donepezil Study Group. Neurology. 1998;50:136\u201345. https:\/\/doi.org\/10.1212\/WNL.50.1.136.","journal-title":"Neurology"},{"key":"1017_CR211","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1159\/000017126","volume":"10","author":"A Burns","year":"1999","unstructured":"Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer\u2019s disease: results from a multinational trial. Dement Geriatr Cogn Disord. 1999;10:237\u201344. https:\/\/doi.org\/10.1159\/000017126.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1017_CR212","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1159\/000017259","volume":"11","author":"A Homma","year":"2000","unstructured":"Homma A, Takeda M, Imai Y, et al. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer\u2019s disease: a 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group. Dement Geriatr Cogn Disord. 2000;11:299\u2013313. https:\/\/doi.org\/10.1159\/000017259.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1017_CR213","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3233\/JAD-151149","volume":"52","author":"A Homma","year":"2016","unstructured":"Homma A, Atarashi H, Kubota N, et al. Efficacy and safety of sustained release donepezil high dose versus immediate release donepezil standard dose in Japanese patients with severe Alzheimer\u2019s disease: a randomized, double-blind trial. J Alzheimers Dis. 2016;52:345\u201357. https:\/\/doi.org\/10.3233\/JAD-151149.","journal-title":"J Alzheimers Dis"},{"key":"1017_CR214","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/ANE.12571","volume":"135","author":"SH Han","year":"2017","unstructured":"Han SH, Lee JH, Kim SY, et al. Donepezil 23 mg in Asian patients with moderate-to-severe Alzheimer\u2019s disease. Acta Neurol Scand. 2017;135:252\u20136. https:\/\/doi.org\/10.1111\/ANE.12571.","journal-title":"Acta Neurol Scand"},{"key":"1017_CR215","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2165\/00002512-200825020-00008","volume":"25","author":"RS Doody","year":"2008","unstructured":"Doody RS, Corey-Bloom J, Zhang R, et al. Safety and tolerability of donepezil at doses up to 20 mg\/day: results from a pilot study in patients with Alzheimer\u2019s disease. Drugs Aging. 2008;25:163\u201374. https:\/\/doi.org\/10.2165\/00002512-200825020-00008.","journal-title":"Drugs Aging"},{"key":"1017_CR216","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/S0140-6736(06)68350-5","volume":"367","author":"B Winblad","year":"2006","unstructured":"Winblad B, Kilander L, Eriksson S, et al. Donepezil in patients with severe Alzheimer\u2019s disease: double-blind, parallel-group, placebo-controlled study. Lancet. 2006;367:1057\u201365. https:\/\/doi.org\/10.1016\/S0140-6736(06)68350-5.","journal-title":"Lancet"},{"key":"1017_CR217","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1212\/01.WNL.0000266627.96040.5A","volume":"69","author":"SE Black","year":"2007","unstructured":"Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology. 2007;69:459\u201369. https:\/\/doi.org\/10.1212\/01.WNL.0000266627.96040.5A.","journal-title":"Neurology"},{"key":"1017_CR218","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-11-21","author":"M Sabbagh","year":"2011","unstructured":"Sabbagh M, Cummings J. Progressive cholinergic decline in Alzheimer\u2019s disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology. BMC Neurol. 2011. https:\/\/doi.org\/10.1186\/1471-2377-11-21.","journal-title":"BMC Neurol"},{"key":"1017_CR219","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/JCP.0000000000000726","volume":"37","author":"C Lee","year":"2017","unstructured":"Lee C, Lee K, Yu H, et al. Adverse events with sustained-release donepezil in Alzheimer disease: relation to body mass index. J Clin Psychopharmacol. 2017;37:401\u20134. https:\/\/doi.org\/10.1097\/JCP.0000000000000726.","journal-title":"J Clin Psychopharmacol"},{"key":"1017_CR220","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1212\/CPJ.0B013E318278BEBD","volume":"2","author":"DS Knopman","year":"2012","unstructured":"Knopman DS. Donepezil 23 mg: an empty suit. Neurol Clin Pract. 2012;2:352\u20135. https:\/\/doi.org\/10.1212\/CPJ.0B013E318278BEBD.","journal-title":"Neurol Clin Pract."},{"key":"1017_CR221","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/CNS.12076","volume":"19","author":"JL Cummings","year":"2013","unstructured":"Cummings JL, Geldmacher D, Farlow M, et al. High-dose donepezil (23 mg\/day) for the treatment of moderate and severe Alzheimer\u2019s disease: drug profile and clinical guidelines. CNS Neurosci Ther. 2013;19:294\u2013301. https:\/\/doi.org\/10.1111\/CNS.12076.","journal-title":"CNS Neurosci Ther"},{"key":"1017_CR222","doi-asserted-by":"publisher","DOI":"10.1186\/S13195-019-0492-1","author":"YJ Hong","year":"2019","unstructured":"Hong YJ, Han HJ, Youn YC, et al. Safety and tolerability of donepezil 23 mg with or without intermediate dose titration in patients with Alzheimer\u2019s disease taking donepezil 10 mg: a multicenter, randomized, open-label, parallel-design, three-arm, prospective trial. Alzheimers Res Ther. 2019. https:\/\/doi.org\/10.1186\/S13195-019-0492-1.","journal-title":"Alzheimers Res Ther."},{"key":"1017_CR223","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/S12640-016-9672-Y","volume":"31","author":"M Valis","year":"2017","unstructured":"Valis M, Masopust J, Vysata O, et al. Concentration of donepezil in the cerebrospinal fluid of AD patients: evaluation of dosage sufficiency in standard treatment strategy. Neurotox Res. 2017;31:162\u20138. https:\/\/doi.org\/10.1007\/S12640-016-9672-Y.","journal-title":"Neurotox Res"},{"key":"1017_CR224","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000281847.17519.E0","author":"B Winblad","year":"2007","unstructured":"Winblad B, Grossberg G, Fr\u00f6lich L, et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology. 2007. https:\/\/doi.org\/10.1212\/01.WNL.0000281847.17519.E0.","journal-title":"Neurology"},{"key":"1017_CR225","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/J.1742-1241.2011.02641.X","volume":"65","author":"GT Grossberg","year":"2011","unstructured":"Grossberg GT, Olin JT, Somogyi M, Meng X. Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer\u2019s disease. Int J Clin Pract. 2011;65:465\u201371. https:\/\/doi.org\/10.1111\/J.1742-1241.2011.02641.X.","journal-title":"Int J Clin Pract"},{"key":"1017_CR226","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/GPS.2669","volume":"26","author":"MR Farlow","year":"2011","unstructured":"Farlow MR, Grossberg GT, Meng X, et al. Rivastigmine transdermal patch and capsule in Alzheimer\u2019s disease: influence of disease stage on response to therapy. Int J Geriatr Psychiatry. 2011;26:1236\u201343. https:\/\/doi.org\/10.1002\/GPS.2669.","journal-title":"Int J Geriatr Psychiatry"},{"key":"1017_CR227","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000281846.40390.50","author":"J Cummings","year":"2007","unstructured":"Cummings J, Lef\u00e8vre G, Small G, Appel-Dingemanse S. Pharmacokinetic rationale for the rivastigmine patch. Neurology. 2007. https:\/\/doi.org\/10.1212\/01.WNL.0000281846.40390.50.","journal-title":"Neurology"},{"key":"1017_CR228","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1212\/WNL.54.12.2269","volume":"54","author":"PN Tariot","year":"2000","unstructured":"Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology. 2000;54:2269\u201376. https:\/\/doi.org\/10.1212\/WNL.54.12.2269.","journal-title":"Neurology"},{"key":"1017_CR229","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1212\/WNL.54.12.2261","volume":"54","author":"MA Raskind","year":"2000","unstructured":"Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology. 2000;54:2261\u20138. https:\/\/doi.org\/10.1212\/WNL.54.12.2261.","journal-title":"Neurology"},{"key":"1017_CR230","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1136\/BMJ.321.7274.1445","volume":"321","author":"GK Wilcock","year":"2000","unstructured":"Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer\u2019s disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ. 2000;321:1445\u20139. https:\/\/doi.org\/10.1136\/BMJ.321.7274.1445.","journal-title":"BMJ"},{"key":"1017_CR231","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1002\/GPS.409","volume":"16","author":"D Wilkinson","year":"2001","unstructured":"Wilkinson D, Murray J. Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer\u2019s disease. Int J Geriatr Psychiatry. 2001;16:852\u20137. https:\/\/doi.org\/10.1002\/GPS.409.","journal-title":"Int J Geriatr Psychiatry"},{"key":"1017_CR232","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1136\/JNNP.71.5.589","volume":"71","author":"K Rockwood","year":"2001","unstructured":"Rockwood K, Mintzer J, Truyen L, et al. Effects of a flexible galantamine dose in Alzheimer\u2019s disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry. 2001;71:589\u201395. https:\/\/doi.org\/10.1136\/JNNP.71.5.589.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1017_CR233","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/J.CLINTHERA.2004.10.006","volume":"26","author":"GH Suh","year":"2004","unstructured":"Suh GH, Yeon Jung H, Uk Lee C, et al. A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer\u2019s disease in a Korean population. Clin Ther. 2004;26:1608\u201318. https:\/\/doi.org\/10.1016\/J.CLINTHERA.2004.10.006.","journal-title":"Clin Ther"},{"key":"1017_CR234","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1159\/000086613","volume":"20","author":"H Brodaty","year":"2005","unstructured":"Brodaty H, Corey-Bloom J, Potocnik FCV, et al. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer\u2019s disease. Dement Geriatr Cogn Disord. 2005;20:120\u201332. https:\/\/doi.org\/10.1159\/000086613.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1017_CR235","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1503\/CMAJ.051432","volume":"174","author":"K Rockwood","year":"2006","unstructured":"Rockwood K, Fay S, Song X, et al. Attainment of treatment goals by people with Alzheimer\u2019s disease receiving galantamine: a randomized controlled trial. CMAJ. 2006;174:1099\u2013105. https:\/\/doi.org\/10.1503\/CMAJ.051432.","journal-title":"CMAJ"},{"key":"1017_CR236","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/J.1468-1331.2004.00885.X","volume":"11","author":"T Pirttil\u00e4","year":"2004","unstructured":"Pirttil\u00e4 T, Wilcock G, Truyen L, Damaraju CV. Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer\u2019s disease: multicenter trial. Eur J Neurol. 2004;11:734\u201341. https:\/\/doi.org\/10.1111\/J.1468-1331.2004.00885.X.","journal-title":"Eur J Neurol"},{"key":"1017_CR237","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1001\/ARCHNEUR.61.2.252","volume":"61","author":"MA Raskind","year":"2004","unstructured":"Raskind MA, Peskind ER, Truyen L, et al. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch Neurol. 2004;61:252\u20136. https:\/\/doi.org\/10.1001\/ARCHNEUR.61.2.252.","journal-title":"Arch Neurol"},{"key":"1017_CR238","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1176\/APPI.AJGP.12.5.473","volume":"12","author":"C Lyketsos","year":"2004","unstructured":"Lyketsos C, Reichman W, Kershaw P, Zhu Y. Long-term outcomes of galantamine treatment in patients with Alzheimer disease. Am J Geriatr Psychiatry. 2004;12:473\u201382. https:\/\/doi.org\/10.1176\/APPI.AJGP.12.5.473.","journal-title":"Am J Geriatr Psychiatry"},{"key":"1017_CR239","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/02687038.2013.793283","volume":"28","author":"AD Falchook","year":"2014","unstructured":"Falchook AD, Heilman KM, Finney GR, et al. Neuroplasticity, neurotransmitters and new directions for treatment of anomia in Alzheimer disease. Aphasiology. 2014;28:219\u201335.","journal-title":"Aphasiology"},{"key":"1017_CR240","doi-asserted-by":"publisher","first-page":"E68","DOI":"10.1093\/BRAIN\/AWY204","volume":"141","author":"S Gauthier","year":"2018","unstructured":"Gauthier S, Herrmann N, Rosa-Neto P. Optimal use of cholinergic drugs in Alzheimer\u2019s disease. Brain. 2018;141:E68. https:\/\/doi.org\/10.1093\/BRAIN\/AWY204.","journal-title":"Brain"},{"key":"1017_CR241","first-page":"435","volume":"25","author":"CM Thiel","year":"2007","unstructured":"Thiel CM. Pharmacological modulation of learning-induced plasticity in human auditory cortex. Restor Neurol Neurosci. 2007;25:435\u201343.","journal-title":"Restor Neurol Neurosci"},{"key":"1017_CR242","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1016\/S0140-6736(20)30689-9","volume":"395","author":"J Fortea","year":"2020","unstructured":"Fortea J, Vilaplana E, Carmona-Iragui M, et al. Clinical and biomarker changes of Alzheimer\u2019s disease in adults with Down syndrome: a cross-sectional study. Lancet. 2020;395:1988\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(20)30689-9.","journal-title":"Lancet"},{"key":"1017_CR243","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/AJMG.C.31439","volume":"169","author":"J Grieco","year":"2015","unstructured":"Grieco J, Pulsifer M, Seligsohn K, et al. Down syndrome: cognitive and behavioral functioning across the lifespan. Am J Med Genet C Semin Med Genet. 2015;169:135\u201349. https:\/\/doi.org\/10.1002\/AJMG.C.31439.","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"1017_CR244","doi-asserted-by":"publisher","DOI":"10.3390\/MOLECULES27103244","author":"LC de Oliveira","year":"2022","unstructured":"de Oliveira LC, Faria DDP. Pharmacological approaches to the treatment of dementia in Down syndrome: a systematic review of randomized clinical studies. Molecules. 2022. https:\/\/doi.org\/10.3390\/MOLECULES27103244.","journal-title":"Molecules"},{"key":"1017_CR245","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011546.PUB2","author":"N Livingstone","year":"2015","unstructured":"Livingstone N, Hanratty J, Mcshane R, Macdonald G. Pharmacological interventions for cognitive decline in people with Down syndrome. Cochrane Database Syst Rev. 2015. https:\/\/doi.org\/10.1002\/14651858.CD011546.PUB2.","journal-title":"Cochrane Database Syst Rev"},{"key":"1017_CR246","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/AJMG.A.10074","volume":"116A","author":"JH Heller","year":"2003","unstructured":"Heller JH, Spiridigliozzi GA, Sullivan JA, et al. Donepezil for the treatment of language deficits in adults with Down syndrome: a preliminary 24-week open trial. Am J Med Genet A. 2003;116A:111\u20136. https:\/\/doi.org\/10.1002\/AJMG.A.10074.","journal-title":"Am J Med Genet A"},{"key":"1017_CR247","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1093\/BRAIN\/AWU024","volume":"137","author":"MM Mesulam","year":"2014","unstructured":"Mesulam MM, Weintraub S, Rogalski EJ, et al. Asymmetry and heterogeneity of Alzheimer\u2019s and frontotemporal pathology in primary progressive aphasia. Brain. 2014;137:1176\u201392. https:\/\/doi.org\/10.1093\/BRAIN\/AWU024.","journal-title":"Brain"},{"key":"1017_CR248","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/ANA.410110607","volume":"11","author":"M-M Mesulam","year":"1982","unstructured":"Mesulam M-M. Slowly progressive aphasia without generalized dementia. Ann Neurol. 1982;11:592\u20138. https:\/\/doi.org\/10.1002\/ANA.410110607.","journal-title":"Ann Neurol"},{"key":"1017_CR249","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/ana.25333","volume":"84","author":"D Bergeron","year":"2018","unstructured":"Bergeron D, Gorno-Tempini ML, Rabinovici GD, et al. Prevalence of amyloid-\u03b2 pathology in distinct variants of primary progressive aphasia. Ann Neurol. 2018;84:729\u201340. https:\/\/doi.org\/10.1002\/ana.25333.","journal-title":"Ann Neurol"},{"key":"1017_CR250","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/S00415-016-8324-8","volume":"264","author":"A Villarejo-Galende","year":"2017","unstructured":"Villarejo-Galende A, Llamas-Velasco S, G\u00f3mez-Grande A, et al. Amyloid pet in primary progressive aphasia: case series and systematic review of the literature. J Neurol. 2017;264:121\u201330. https:\/\/doi.org\/10.1007\/S00415-016-8324-8.","journal-title":"J Neurol"},{"key":"1017_CR251","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1001\/JAMANEUROL.2017.4309","volume":"75","author":"MA Santos-Santos","year":"2018","unstructured":"Santos-Santos MA, Rabinovici GD, Iaccarino L, et al. Rates of amyloid imaging positivity in patients with primary progressive aphasia. JAMA Neurol. 2018;75:342\u201352. https:\/\/doi.org\/10.1001\/JAMANEUROL.2017.4309.","journal-title":"JAMA Neurol"},{"key":"1017_CR252","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1212\/WNL.0000000000004034","volume":"88","author":"LAA Giannini","year":"2017","unstructured":"Giannini LAA, Irwin DJ, Mcmillan CT, et al. Clinical marker for Alzheimer disease pathology in logopenic primary progressive aphasia. Neurology. 2017;88:2276\u201384. https:\/\/doi.org\/10.1212\/WNL.0000000000004034.","journal-title":"Neurology"},{"key":"1017_CR253","doi-asserted-by":"publisher","first-page":"581","DOI":"10.3233\/JAD-150812","volume":"51","author":"E Louwersheimer","year":"2016","unstructured":"Louwersheimer E, Keulen MA, Steenwijk MD, et al. Heterogeneous language profiles in patients with primary progressive aphasia due to Alzheimer\u2019s disease. J Alzheimers Dis. 2016;51:581\u201390. https:\/\/doi.org\/10.3233\/JAD-150812.","journal-title":"J Alzheimers Dis"},{"key":"1017_CR254","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/J.CORTEX.2012.12.006","volume":"55","author":"KC Fraser","year":"2014","unstructured":"Fraser KC, Meltzer JA, Graham NL, et al. Automated classification of primary progressive aphasia subtypes from narrative speech transcripts. Cortex. 2014;55:43\u201360. https:\/\/doi.org\/10.1016\/J.CORTEX.2012.12.006.","journal-title":"Cortex"},{"key":"1017_CR255","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1159\/000113034","volume":"25","author":"A Kertesz","year":"2008","unstructured":"Kertesz A, Morlog D, Light M, et al. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord. 2008;25:178\u201385. https:\/\/doi.org\/10.1159\/000113034.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1017_CR256","doi-asserted-by":"publisher","DOI":"10.3389\/FNEUR.2020.00049","author":"H Watanabe","year":"2020","unstructured":"Watanabe H, Ikeda M, Mori E. Primary progressive aphasia as a prodromal state of dementia with Lewy bodies: a case report. Front Neurol. 2020. https:\/\/doi.org\/10.3389\/FNEUR.2020.00049.","journal-title":"Front Neurol"},{"key":"1017_CR257","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1136\/PRACTNEUROL-2018-001921","volume":"20","author":"A Volkmer","year":"2020","unstructured":"Volkmer A, Rogalski E, Henry M, et al. Speech and language therapy approaches to managing primary progressive aphasia. Pract Neurol. 2020;20:154\u201362. https:\/\/doi.org\/10.1136\/PRACTNEUROL-2018-001921.","journal-title":"Pract Neurol"},{"key":"1017_CR258","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3233\/JAD-190654","volume":"73","author":"S Emrani","year":"2020","unstructured":"Emrani S, Lamar M, Price CC, et al. Alzheimer\u2019s\/vascular spectrum dementia: classification in addition to diagnosis. J Alzheimers Dis. 2020;73:63\u201371. https:\/\/doi.org\/10.3233\/JAD-190654.","journal-title":"J Alzheimers Dis"},{"key":"1017_CR259","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/S13311-021-01170-Y","volume":"19","author":"T Rundek","year":"2022","unstructured":"Rundek T, Tolea M, Ariko T, et al. Vascular cognitive impairment (VCI). Neurotherapeutics. 2022;19:68\u201388. https:\/\/doi.org\/10.1007\/S13311-021-01170-Y.","journal-title":"Neurotherapeutics"},{"key":"1017_CR260","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/J.JALZ.2006.09.002","volume":"3","author":"KA Jellinger","year":"2007","unstructured":"Jellinger KA. The enigma of mixed dementia. Alzheimers Dement. 2007;3:40\u201353. https:\/\/doi.org\/10.1016\/J.JALZ.2006.09.002.","journal-title":"Alzheimers Dement"},{"key":"1017_CR261","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/J.JNS.2010.08.038","volume":"299","author":"KA Jellinger","year":"2010","unstructured":"Jellinger KA, Attems J. Is there pure vascular dementia in old age? J Neurol Sci. 2010;299:150\u20134. https:\/\/doi.org\/10.1016\/J.JNS.2010.08.038.","journal-title":"J Neurol Sci"},{"key":"1017_CR262","doi-asserted-by":"publisher","DOI":"10.1038\/NRDP.2018.3","author":"WM van der Flier","year":"2018","unstructured":"van der Flier WM, Skoog I, Schneider JA, et al. Vascular cognitive impairment. Nat Rev Dis Primers. 2018. https:\/\/doi.org\/10.1038\/NRDP.2018.3.","journal-title":"Nat Rev Dis Primers"},{"key":"1017_CR263","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1212\/CON.0000000000001124","volume":"28","author":"E Chang Wong","year":"2022","unstructured":"Chang Wong E, Chang CH. Vascular cognitive impairment and dementia. Continuum (Minneap Minn). 2022;28:750\u201380. https:\/\/doi.org\/10.1212\/CON.0000000000001124.","journal-title":"Continuum (Minneap Minn)."},{"key":"1017_CR264","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1684\/pnv.2014.0466","volume":"12","author":"J Macoir","year":"2014","unstructured":"Macoir J, Laforce RJ, Monetta L, Wilson M. Language deficits in major forms of dementia and primary progressive aphasias: an update according to new diagnostic criteria. G\u00e9riatri Psychol Neuropsychiatr Viel. 2014;12:199\u2013208. https:\/\/doi.org\/10.1684\/pnv.2014.0466.","journal-title":"G\u00e9riatri Psychol Neuropsychiatr Viel."},{"key":"1017_CR265","doi-asserted-by":"publisher","DOI":"10.1016\/J.CCCB.2021.100029","author":"E Lowry","year":"2021","unstructured":"Lowry E, Puthusseryppady V, Johnen AK, et al. Cognitive and neuroimaging markers for preclinical vascular cognitive impairment. Cereb Circ Cogn Behav. 2021. https:\/\/doi.org\/10.1016\/J.CCCB.2021.100029.","journal-title":"Cereb Circ Cogn Behav."},{"key":"1017_CR266","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1161\/STROKEAHA.109.570077","volume":"41","author":"GC Rom\u00e1n","year":"2010","unstructured":"Rom\u00e1n GC, Salloway S, Black SE, et al. Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size. Stroke. 2010;41:1213\u201321. https:\/\/doi.org\/10.1161\/STROKEAHA.109.570077.","journal-title":"Stroke"},{"key":"1017_CR267","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/BF01243383","volume":"73","author":"JO Rinne","year":"1988","unstructured":"Rinne JO, S\u00e4k\u00f6 E, Palj\u00e4rvi L, et al. A comparison of brain choline acetyltransferase activity in Alzheimer\u2019s disease, multi-infarct dementia, and combined dementia. J Neural Transm. 1988;73:121\u20138. https:\/\/doi.org\/10.1007\/BF01243383.","journal-title":"J Neural Transm"},{"key":"1017_CR268","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1212\/01.WNL.0000148591.63727.80","volume":"64","author":"E Perry","year":"2005","unstructured":"Perry E, Ziabreva I, Perry R, et al. Absence of cholinergic deficits in \u201cpure\u201d vascular dementia. Neurology. 2005;64:132\u20133. https:\/\/doi.org\/10.1212\/01.WNL.0000148591.63727.80.","journal-title":"Neurology"},{"key":"1017_CR269","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1159\/000239235","volume":"28","author":"SI Sharp","year":"2009","unstructured":"Sharp SI, Francis PT, Elliott MSJ, et al. Choline acetyltransferase activity in vascular dementia and stroke. Dement Geriatr Cogn Disord. 2009;28:233\u20138. https:\/\/doi.org\/10.1159\/000239235.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1017_CR270","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1212\/01.WNL.0000055927.22611.EB","volume":"60","author":"M Mesulam","year":"2003","unstructured":"Mesulam M, Siddique T, Cohen B. Cholinergic denervation in a pure multi-infarct state: observations on CADASIL. Neurology. 2003;60:1183\u20135. https:\/\/doi.org\/10.1212\/01.WNL.0000055927.22611.EB.","journal-title":"Neurology"},{"key":"1017_CR271","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/ENE.14073","volume":"27","author":"JS Lim","year":"2020","unstructured":"Lim JS, Kwon HM, Lee YS. Effect of cholinergic pathway disruption on cortical and subcortical volumes in subcortical vascular cognitive impairment. Eur J Neurol. 2020;27:210\u20132. https:\/\/doi.org\/10.1111\/ENE.14073.","journal-title":"Eur J Neurol"},{"key":"1017_CR272","doi-asserted-by":"publisher","first-page":"E227512","DOI":"10.1001\/JAMANETWORKOPEN.2022.7512","volume":"5","author":"A Dhana","year":"2022","unstructured":"Dhana A, Decarli C, Dhana K, et al. Association of subjective memory complaints with white matter hyperintensities and cognitive decline among older adults in Chicago, Illinois. JAMA Netw Open. 2022;5:E227512. https:\/\/doi.org\/10.1001\/JAMANETWORKOPEN.2022.7512.","journal-title":"JAMA Netw Open"},{"key":"1017_CR273","doi-asserted-by":"publisher","DOI":"10.1016\/J.ARR.2022.101757","author":"H Pitti","year":"2022","unstructured":"Pitti H, Diaz-Galvan P, Barroso J, et al. Cerebrovascular damage in subjective cognitive decline: a systematic review and meta-analysis. Ageing Res Rev. 2022. https:\/\/doi.org\/10.1016\/J.ARR.2022.101757.","journal-title":"Ageing Res Rev"},{"key":"1017_CR274","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1177\/0271678X17728162","volume":"38","author":"L Zhao","year":"2018","unstructured":"Zhao L, Biesbroek JM, Shi L, et al. Strategic infarct location for post-stroke cognitive impairment: a multivariate lesion-symptom mapping study. J Cereb Blood Flow Metab. 2018;38:1299\u2013311. https:\/\/doi.org\/10.1177\/0271678X17728162.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1017_CR275","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/S1474-4422(21)00060-0","volume":"20","author":"NA Weaver","year":"2021","unstructured":"Weaver NA, Kuijf HJ, Aben HP, et al. Strategic infarct locations for post-stroke cognitive impairment: a pooled analysis of individual patient data from 12 acute ischaemic stroke cohorts. Lancet Neurol. 2021;20:448\u201359. https:\/\/doi.org\/10.1016\/S1474-4422(21)00060-0.","journal-title":"Lancet Neurol"},{"key":"1017_CR276","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1006\/BRLN.1999.2223","volume":"71","author":"JD Hughes","year":"2000","unstructured":"Hughes JD, Jacobs DH, Heilman KM. Neuropharmacology and linguistic neuroplasticity. Brain Lang. 2000;71:96\u2013101. https:\/\/doi.org\/10.1006\/BRLN.1999.2223.","journal-title":"Brain Lang"},{"key":"1017_CR277","doi-asserted-by":"publisher","DOI":"10.3389\/FNEUR.2011.00016","author":"R Riveros","year":"2011","unstructured":"Riveros R, Chabriat H, Flores R, et al. Effects of donepezil on behavioral manifestations of thalamic infarction: a single-case observation. Front Neurol. 2011. https:\/\/doi.org\/10.3389\/FNEUR.2011.00016.","journal-title":"Front Neurol"},{"key":"1017_CR278","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/S40263-017-0459-3","volume":"31","author":"MU Farooq","year":"2017","unstructured":"Farooq MU, Min J, Goshgarian C, Gorelick PB. Pharmacotherapy for vascular cognitive impairment. CNS Drugs. 2017;31:759\u201376. https:\/\/doi.org\/10.1007\/S40263-017-0459-3.","journal-title":"CNS Drugs"},{"key":"1017_CR279","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1161\/01.STR.0000091396.95360.E1","volume":"34","author":"S Black","year":"2003","unstructured":"Black S, Rom\u00e1n GC, Geldmacher DS, et al. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke. 2003;34:2323\u201330. https:\/\/doi.org\/10.1161\/01.STR.0000091396.95360.E1.","journal-title":"Stroke"},{"key":"1017_CR280","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1212\/01.WNL.0000078943.50032.FC","volume":"61","author":"D Wilkinson","year":"2003","unstructured":"Wilkinson D, Doody R, Helme R, et al. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology. 2003;61:479\u201386. https:\/\/doi.org\/10.1212\/01.WNL.0000078943.50032.FC.","journal-title":"Neurology"},{"key":"1017_CR281","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/S1474-4422(08)70046-2","volume":"7","author":"M Dichgans","year":"2008","unstructured":"Dichgans M, Markus HS, Salloway S, et al. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. Lancet Neurol. 2008;7:310\u20138. https:\/\/doi.org\/10.1016\/S1474-4422(08)70046-2.","journal-title":"Lancet Neurol"},{"key":"1017_CR282","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0022-510X(02)00280-0","volume":"203\u20134","author":"R Moretti","year":"2002","unstructured":"Moretti R, Torre P, Antonello RM, et al. Rivastigmine in subcortical vascular dementia: an open 22-month study. J Neurol Sci. 2002;203\u20134:141\u20136. https:\/\/doi.org\/10.1016\/S0022-510X(02)00280-0.","journal-title":"J Neurol Sci"},{"key":"1017_CR283","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/J.1600-0404.2009.01263.X","volume":"121","author":"K Narasimhalu","year":"2010","unstructured":"Narasimhalu K, Effendy S, Sim CH, et al. A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease. Acta Neurol Scand. 2010;121:217\u201324. https:\/\/doi.org\/10.1111\/J.1600-0404.2009.01263.X.","journal-title":"Acta Neurol Scand"},{"key":"1017_CR284","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1185\/03007990802328142","volume":"24","author":"C Ballard","year":"2008","unstructured":"Ballard C, Sauter M, Scheltens P, et al. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Curr Med Res Opin. 2008;24:2561\u201374. https:\/\/doi.org\/10.1185\/03007990802328142.","journal-title":"Curr Med Res Opin"},{"key":"1017_CR285","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S0140-6736(02)08267-3","volume":"359","author":"T Erkinjuntti","year":"2002","unstructured":"Erkinjuntti T, Kurz A, Gauthier S, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer\u2019s disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002;359:1283\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(02)08267-3.","journal-title":"Lancet"},{"key":"1017_CR286","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1212\/01.WNL.0000266625.31615.F6","volume":"69","author":"AP Auchus","year":"2007","unstructured":"Auchus AP, Brashear HR, Salloway S, et al. Galantamine treatment of vascular dementia: a randomized trial. Neurology. 2007;69:448\u201358. https:\/\/doi.org\/10.1212\/01.WNL.0000266625.31615.F6.","journal-title":"Neurology"},{"key":"1017_CR287","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013306.PUB2","author":"CE Battle","year":"2021","unstructured":"Battle CE, Abdul-Rahim AH, Shenkin SD, et al. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis. Cochrane Database Syst Rev. 2021. https:\/\/doi.org\/10.1002\/14651858.CD013306.PUB2.","journal-title":"Cochrane Database Syst Rev"},{"key":"1017_CR288","doi-asserted-by":"publisher","first-page":"943","DOI":"10.2147\/NDT.S2221","volume":"3","author":"V Mok","year":"2007","unstructured":"Mok V, Wong A, Ho S, et al. Rivastigmine in Chinese patients with subcortical vascular dementia. Neuropsychiatr Dis Treat. 2007;3:943\u20138. https:\/\/doi.org\/10.2147\/NDT.S2221.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1017_CR289","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2174\/1567205019666220120112301","volume":"19","author":"X Shi","year":"2022","unstructured":"Shi X, Ren G, Cui Y, Xu Z. Comparative efficacy and acceptability of cholinesterase inhibitors and memantine based on dosage in patients with vascular cognitive impairment: a network meta-analysis. Curr Alzheimer Res. 2022;19:133\u201345. https:\/\/doi.org\/10.2174\/1567205019666220120112301.","journal-title":"Curr Alzheimer Res"},{"issue":"Suppl 2","key":"1017_CR290","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1097\/00002093-199700112-00003","volume":"11","author":"RC Mohs","year":"1997","unstructured":"Mohs RC, Knopman D, Petersen RC, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer\u2019s Disease Assessment Scale that broaden its scope. The Alzheimer\u2019s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(Suppl 2):S13-21.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"1017_CR291","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \u201cMini-mental state\u201d: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189\u201398. https:\/\/doi.org\/10.1016\/0022-3956(75)90026-6.","journal-title":"J Psychiatr Res"},{"key":"1017_CR292","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1212\/WNL.55.11.1621","volume":"55","author":"B Dubois","year":"2000","unstructured":"Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology. 2000;55:1621\u20136. https:\/\/doi.org\/10.1212\/WNL.55.11.1621.","journal-title":"Neurology"},{"key":"1017_CR293","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2190\/5A0F-936P-VG8N-0F5R","volume":"24","author":"PJ Manos","year":"1994","unstructured":"Manos PJ, Wu R. The ten point clock test: a quick screen and grading method for cognitive impairment in medical and surgical patients. Int J Psychiatry Med. 1994;24:229\u201344. https:\/\/doi.org\/10.2190\/5A0F-936P-VG8N-0F5R.","journal-title":"Int J Psychiatry Med"},{"key":"1017_CR294","unstructured":"D\u2019Elia L, Satz P, Uchiyama CL. Color trails test. Psychological Assessment Resources Inc.; 1996."},{"key":"1017_CR295","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3233\/JAD-170991","volume":"63","author":"JK Kueper","year":"2018","unstructured":"Kueper JK, Speechley M, Montero-Odasso M. The Alzheimer\u2019s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): modifications and responsiveness in pre-dementia populations. A narrative review. J Alzheimers Dis. 2018;63:423\u201344. https:\/\/doi.org\/10.3233\/JAD-170991.","journal-title":"J Alzheimers Dis"},{"key":"1017_CR296","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2165\/00002512-200522020-00006","volume":"22","author":"ML Berthier","year":"2005","unstructured":"Berthier ML. Poststroke aphasia: epidemiology, pathophysiology and treatment. Drugs Aging. 2005;22:163\u201382. https:\/\/doi.org\/10.2165\/00002512-200522020-00006.","journal-title":"Drugs Aging"},{"key":"1017_CR297","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1097\/MLR.0B013E3181CA2647","volume":"48","author":"JMC Lam","year":"2010","unstructured":"Lam JMC, Wodchis WP. The relationship of 60 disease diagnoses and 15 conditions to preference-based health-related quality of life in Ontario hospital-based long-term care residents. Med Care. 2010;48:380\u20137. https:\/\/doi.org\/10.1097\/MLR.0B013E3181CA2647.","journal-title":"Med Care"},{"key":"1017_CR298","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1080\/14737175.2017.1373020","volume":"17","author":"S Saxena","year":"2017","unstructured":"Saxena S, Hillis AE. An update on medications and noninvasive brain stimulation to augment language rehabilitation in post-stroke aphasia. Expert Rev Neurother. 2017;17:1091\u2013107. https:\/\/doi.org\/10.1080\/14737175.2017.1373020.","journal-title":"Expert Rev Neurother"},{"key":"1017_CR299","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1161\/STROKEAHA.107.493353","volume":"39","author":"SS Staekenborg","year":"2008","unstructured":"Staekenborg SS, van der Flier WM, van Straaten ECW, et al. Neurological signs in relation to type of cerebrovascular disease in vascular dementia. Stroke. 2008;39:317\u201322. https:\/\/doi.org\/10.1161\/STROKEAHA.107.493353.","journal-title":"Stroke"},{"key":"1017_CR300","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/S0140-6736(17)30067-3","volume":"389","author":"C Breitenstein","year":"2017","unstructured":"Breitenstein C, Grewe T, Fl\u00f6el A, et al. Intensive speech and language therapy in patients with chronic aphasia after stroke: a randomised, open-label, blinded-endpoint, controlled trial in a health-care setting. Lancet. 2017;389:1528\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(17)30067-3.","journal-title":"Lancet"},{"key":"1017_CR301","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1136\/JNNP-2017-315962","volume":"89","author":"B Stahl","year":"2018","unstructured":"Stahl B, Mohr B, B\u00fcscher V, et al. Efficacy of intensive aphasia therapy in patients with chronic stroke: a randomised controlled trial. J Neurol Neurosurg Psychiatry. 2018;89:586\u201392. https:\/\/doi.org\/10.1136\/JNNP-2017-315962.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1017_CR302","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/J.APMR.2021.10.017","volume":"103","author":"A Basilakos","year":"2022","unstructured":"Basilakos A, Hula WD, Johnson LP, et al. Defining the neurobiological mechanisms of action in aphasia therapies: applying the rehabilitation treatment specification system framework to research and practice in aphasia. Arch Phys Med Rehabil. 2022;103:581\u20139. https:\/\/doi.org\/10.1016\/J.APMR.2021.10.017.","journal-title":"Arch Phys Med Rehabil"},{"key":"1017_CR303","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/J.APMR.2021.08.025","volume":"103","author":"J Fridriksson","year":"2022","unstructured":"Fridriksson J, Basilakos A, Boyle M, et al. Demystifying the complexity of aphasia treatment: application of the rehabilitation treatment specification systemx. Arch Phys Med Rehabil. 2022;103:574\u201380. https:\/\/doi.org\/10.1016\/J.APMR.2021.08.025.","journal-title":"Arch Phys Med Rehabil"},{"key":"1017_CR304","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1161\/STROKEAHA.121.035216","volume":"53","author":"MC Brady","year":"2022","unstructured":"Brady MC. Dosage, intensity, and frequency of language therapy for aphasia: a systematic review-based, individual participant data network meta-analysis. Stroke. 2022;53:956\u201367. https:\/\/doi.org\/10.1161\/STROKEAHA.121.035216.","journal-title":"Stroke"},{"key":"1017_CR305","doi-asserted-by":"publisher","DOI":"10.1177\/17474930221097477","author":"MC Brady","year":"2022","unstructured":"Brady MC, Ali M, VandenBerg K, et al. Precision rehabilitation for aphasia by patient age, sex, aphasia severity, and time since stroke? A prespecified, systematic review-based, individual participant data, network, subgroup meta-analysis. Int J Stroke. 2022. https:\/\/doi.org\/10.1177\/17474930221097477.","journal-title":"Int J Stroke"},{"key":"1017_CR306","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/J.APMR.2018.08.177","volume":"100","author":"N Gilmore","year":"2019","unstructured":"Gilmore N, Dwyer M, Kiran S. Benchmarks of significant change after aphasia rehabilitation. Arch Phys Med Rehabil. 2019;100:1131-9.e87. https:\/\/doi.org\/10.1016\/J.APMR.2018.08.177.","journal-title":"Arch Phys Med Rehabil"},{"key":"1017_CR307","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09602011.2020.1786412","volume":"31","author":"SR Harvey","year":"2021","unstructured":"Harvey SR, Carragher M, Dickey MW, et al. Treatment dose in post-stroke aphasia: a systematic scoping review. Neuropsychol Rehabil. 2021;31:1\u201332. https:\/\/doi.org\/10.1080\/09602011.2020.1786412.","journal-title":"Neuropsychol Rehabil"},{"key":"1017_CR308","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1177\/1747493018806200","volume":"14","author":"SJ Wallace","year":"2019","unstructured":"Wallace SJ, Worrall L, Rose T, et al. A core outcome set for aphasia treatment research: the ROMA consensus statement. Int J Stroke. 2019;14:180\u20135. https:\/\/doi.org\/10.1177\/1747493018806200.","journal-title":"Int J Stroke"},{"key":"1017_CR309","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1080\/02687038.2013.861057","volume":"28","author":"ML Berthier","year":"2013","unstructured":"Berthier ML, D\u00e1vila G, Green-Heredia C, et al. Massed sentence repetition training can augment and speed up recovery of speech production deficits in patients with chronic conduction aphasia receiving donepezil treatment. Aphasiology. 2013;28:188\u2013218. https:\/\/doi.org\/10.1080\/02687038.2013.861057.","journal-title":"Aphasiology"},{"key":"1017_CR310","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1136\/JNNP-2016-314621","volume":"88","author":"ZVJ Woodhead","year":"2017","unstructured":"Woodhead ZVJ, Crinion J, Teki S, et al. Auditory training changes temporal lobe connectivity in \u201cWernicke\u2019s aphasia\u201d: a randomised trial. J Neurol Neurosurg Psychiatry. 2017;88:586\u201394. https:\/\/doi.org\/10.1136\/JNNP-2016-314621.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1017_CR311","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1136\/JNNP-2012-302268","volume":"83","author":"JM Hong","year":"2012","unstructured":"Hong JM, Shin DH, Lim TS, et al. Galantamine administration in chronic post-stroke aphasia. J Neurol Neurosurg Psychiatry. 2012;83:675\u201380. https:\/\/doi.org\/10.1136\/JNNP-2012-302268.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1017_CR312","first-page":"115","volume":"49","author":"Y Chen","year":"2010","unstructured":"Chen Y, Li Y-S, Wang Z-Y, et al. The efficacy of donepezil for post-stroke aphasia: a pilot case control study. Zhonghua Nei Ke Za Zhi. 2010;49:115\u20138.","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"1017_CR313","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1212\/01.WNL.0000055871.82308.41","volume":"60","author":"ML Berthier","year":"2003","unstructured":"Berthier ML, Hinojosa J, Mart\u00edn MDC, Fern\u00e1ndez I. Open-label study of donepezil in chronic poststroke aphasia. Neurology. 2003;60:1218\u20139. https:\/\/doi.org\/10.1212\/01.WNL.0000055871.82308.41.","journal-title":"Neurology"},{"key":"1017_CR314","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/WNF.0000000000000089","volume":"38","author":"SY Yoon","year":"2015","unstructured":"Yoon SY, Kim JK, An YS, Kim YW. Effect of donepezil on Wernicke aphasia after bilateral middle cerebral artery infarction: subtraction analysis of brain F-18 fluorodeoxyglucose positron emission tomographic images. Clin Neuropharmacol. 2015;38:147\u201350. https:\/\/doi.org\/10.1097\/WNF.0000000000000089.","journal-title":"Clin Neuropharmacol"},{"key":"1017_CR315","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0093-934X(03)00259-1","volume":"87","author":"GV Pashek","year":"2003","unstructured":"Pashek GV, Bachman DL. Cognitive, linguistic and motor speech effects of donepezil hydrochloride in a patient with stroke-related aphasia and apraxia of speech. Brain Lang. 2003;87:179\u201380. https:\/\/doi.org\/10.1016\/S0093-934X(03)00259-1.","journal-title":"Brain Lang"},{"key":"1017_CR316","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1590\/1980-57642018DN13-020015","volume":"13","author":"R Nitrini","year":"2019","unstructured":"Nitrini R, Lucato LT, Sitta MC, et al. Preserved repetition in thalamic afasia: a pathophysiological hypothesis. Dement Neuropsychol. 2019;13:244\u20139. https:\/\/doi.org\/10.1590\/1980-57642018DN13-020015.","journal-title":"Dement Neuropsychol."},{"key":"1017_CR317","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/S11065-011-9177-7","volume":"21","author":"ML Berthier","year":"2011","unstructured":"Berthier ML, Pulverm\u00fcller F, D\u00e1vila G, et al. Drug therapy of post-stroke aphasia: a review of current evidence. Neuropsychol Rev. 2011;21:302\u201317. https:\/\/doi.org\/10.1007\/S11065-011-9177-7.","journal-title":"Neuropsychol Rev"},{"key":"1017_CR318","doi-asserted-by":"publisher","DOI":"10.3390\/JCM10173778","author":"N Cichon","year":"2021","unstructured":"Cichon N, Wlodarczyk L, Saluk-Bijak J, et al. Novel advances to post-stroke aphasia pharmacology and rehabilitation. J Clin Med. 2021. https:\/\/doi.org\/10.3390\/JCM10173778.","journal-title":"J Clin Med"},{"key":"1017_CR319","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/BRAINSCI11010041","volume":"11","author":"C Picano","year":"2021","unstructured":"Picano C, Quadrini A, Pisano F, Marangolo P. Adjunctive approaches to aphasia rehabilitation: a review on efficacy and safety. Brain Sci. 2021;11:1\u201329. https:\/\/doi.org\/10.3390\/BRAINSCI11010041.","journal-title":"Brain Sci"},{"key":"1017_CR320","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1177\/17474930211017807","volume":"16","author":"E Vitti","year":"2021","unstructured":"Vitti E, Hillis AE. Treatment of post-stroke aphasia: a narrative review for stroke neurologists. Int J Stroke. 2021;16:1002\u20138. https:\/\/doi.org\/10.1177\/17474930211017807.","journal-title":"Int J Stroke"},{"key":"1017_CR321","doi-asserted-by":"publisher","DOI":"10.3390\/BRAINSCI12101273","author":"M Katsari","year":"2022","unstructured":"Katsari M, Angelopoulou G, Laskaris N, et al. Common neuroanatomical substrate of cholinergic pathways and language-related brain regions as an explanatory framework for evaluating the efficacy of cholinergic pharmacotherapy in post-stroke aphasia: a review. Brain Sci. 2022. https:\/\/doi.org\/10.3390\/BRAINSCI12101273.","journal-title":"Brain Sci"},{"key":"1017_CR322","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2174\/1871527317666180706143051","volume":"17","author":"X Zhang","year":"2018","unstructured":"Zhang X, Shu B, Zhang D, et al. The efficacy and safety of pharmacological treatments for post-stroke aphasia. CNS Neurol Disord Drug Targets. 2018;17:509\u201321. https:\/\/doi.org\/10.2174\/1871527317666180706143051.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"1017_CR323","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/14737175.2020.1855976","volume":"21","author":"SM Sheppard","year":"2021","unstructured":"Sheppard SM, Sebastian R. Diagnosing and managing post-stroke aphasia. Expert Rev Neurother. 2021;21:221\u201334. https:\/\/doi.org\/10.1080\/14737175.2020.1855976.","journal-title":"Expert Rev Neurother"},{"key":"1017_CR324","doi-asserted-by":"publisher","DOI":"10.1002\/TRC2.12295","author":"J Cummings","year":"2022","unstructured":"Cummings J, Lee G, Nahed P, et al. Alzheimer\u2019s disease drug development pipeline: 2022. Alzheimers Dement (NY). 2022. https:\/\/doi.org\/10.1002\/TRC2.12295.","journal-title":"Alzheimers Dement (NY)."},{"key":"1017_CR325","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1016\/S0140-6736(04)16499-4","volume":"363","author":"C Courtney","year":"2004","unstructured":"Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer\u2019s disease (AD2000): randomised double-blind trial. Lancet. 2004;363:2105\u201315. https:\/\/doi.org\/10.1016\/S0140-6736(04)16499-4.","journal-title":"Lancet"},{"key":"1017_CR326","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/S0140-6736(04)16533-1","volume":"363","author":"LS Schneider","year":"2004","unstructured":"Schneider LS. AD2000: donepezil in Alzheimer\u2019s disease. Lancet. 2004;363:2100\u20131. https:\/\/doi.org\/10.1016\/S0140-6736(04)16533-1.","journal-title":"Lancet"},{"key":"1017_CR327","doi-asserted-by":"publisher","first-page":"S82","DOI":"10.4103\/AIAN.AIAN_549_20","volume":"23","author":"SE Duncan","year":"2020","unstructured":"Duncan SE, Pradeep AA, Small SL. A review of biological interventions in chronic aphasia. Ann Indian Acad Neurol. 2020;23:S82\u201394. https:\/\/doi.org\/10.4103\/AIAN.AIAN_549_20.","journal-title":"Ann Indian Acad Neurol"},{"key":"1017_CR328","doi-asserted-by":"publisher","DOI":"10.1002\/GPS.935","author":"E Giacobini","year":"2003","unstructured":"Giacobini E. Cholinergic function and Alzheimer\u2019s disease. Int J Geriatr Psychiatry. 2003. https:\/\/doi.org\/10.1002\/GPS.935.","journal-title":"Int J Geriatr Psychiatry"},{"key":"1017_CR329","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1212\/01.CON.0000429180.60095.D0","volume":"19","author":"LS Schneider","year":"2013","unstructured":"Schneider LS. Alzheimer disease pharmacologic treatment and treatment research. Continuum (Minneap Minn). 2013;19:339\u201357. https:\/\/doi.org\/10.1212\/01.CON.0000429180.60095.D0.","journal-title":"Continuum (Minneap Minn)."},{"key":"1017_CR330","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21597","author":"ML Berthier","year":"2009","unstructured":"Berthier ML, Green C, Lara JP, et al. Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia. Ann Neurol. 2009. https:\/\/doi.org\/10.1002\/ana.21597.","journal-title":"Ann Neurol"},{"key":"1017_CR331","doi-asserted-by":"publisher","DOI":"10.1080\/02687038.2013.861057","author":"ML Berthier","year":"2014","unstructured":"Berthier ML, D\u00e1vila G, Green-Heredia C, et al. Massed sentence repetition training can augment and speed up recovery of speech production deficits in patients with chronic conduction aphasia receiving donepezil treatment. Aphasiology. 2014. https:\/\/doi.org\/10.1080\/02687038.2013.861057.","journal-title":"Aphasiology"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01017-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-023-01017-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01017-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T14:28:25Z","timestamp":1690468105000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-023-01017-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,21]]},"references-count":331,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1017"],"URL":"https:\/\/doi.org\/10.1007\/s40263-023-01017-4","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,21]]},"assertion":[{"value":"24 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Funding for open access publishing: Universidad M\u00e1laga\/CBUA. Guadalupe D\u00e1vila was supported by the Junta de Andaluc\u00eda, Spain (Grant: P20_00501). Marcelo L. Berthier has been supported by the European Social Fund (FEDER: EQC2018-004803-P). Mar\u00eda Jos\u00e9 Torres-Prioris was supported by a Margarita Salas postdoctoral fellowship by the University of Malaga, funded by the European Union, NextGenerationEU, and the Spanish Ministerio de Universidades. Diana L\u00f3pez-Barroso was supported by the Ayuda RYC2020-029495-I Ram\u00f3n y Cajal funded by the MCIN\/AEI\/10.13039\/501100011033 and by El FSE invierte en tu futuro; and by the Grant PID2021-127617NA-I00 Proyecto de Generaci\u00f3n de Conocimiento 2021 funded by MCIN\/AEI\/10.13039\/501100011033 and FEDER Una manera de hacer Europa. Funding for the open access charge: Universidad de M\u00e1laga\/CBUA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Guadalupe D\u00e1vila, Mar\u00eda Jos\u00e9 Torres-Prioris, and Diana L\u00f3pez-Barroso have no conflicts of interest that are directly relevant to the content of this article. Marcelo L. Berthier was funded by an independent research grant by Pfizer Spain and Eisai for the referenced study by Berthier et al. (2023). The principal investigator designed, conducted, and controlled the study, and Pfizer Spain provided donepezil.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the article and have read and approved the submitted version. GD, MJT-P, DL-B, and MLB substantially contributed to the conception and design of the article, as well as the interpretation of the relevant literature. All authors contributed to drafting several versions of the manuscript and revised it critically for important intellectual content. MLB formulated the idea for the publication and critically revised the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}